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Abstract
Co-Transcriptional Splicing in Murine Erythroblasts
Kirsten Audrey Reimer
2021
Eukaryotic genes contain non-coding sequences called introns. The removal of
introns from pre-mRNAs, termed splicing, is carried out by the spliceosome, a
multi-megadalton molecular complex of proteins and RNAs. Splicing occurs co-
transcriptionally across multiple cell types and species. The Neugebauer lab has
developed single molecule nascent RNA sequencing methods—including single
molecule intron tracking (SMIT) and long-read sequencing (LRS) of nascent RNA—
to visualize the precursors, intermediates, and products of transcription and splic-
ing in budding and fission yeasts. Using these methods, the lab was able to estimate
the kinetics of single intron removal in both yeasts by relating the 3′ end of nascent
RNA (the position of RNA Polymerase II) to progress of the splicing reaction. In
both species of yeast, splicing proceeded rapidly and co-transcriptionally.
In comparison to yeast, mammalian genes are much more complex—on aver-
age they contain eight long introns surrounded by short exons. It was unclear how
the presence of many more long introns, often with more poorly conserved splice
site sequences, would affect how splicing and transcription are coordinated. Thus, I
have optimized new methods to isolate nascent RNAand analyze co-transcriptional
splicing in mammalian cells.
To determine how splicing is integrated with transcription elongation and 3′
end formation in mammalian cells, I performed long-read sequencing of individ-
ual nascent RNAs and PRO-seq during murine erythropoiesis. I chose murine ery-
throid leukemia (MEL) cells as a model system, as they can be easily differenti-
ated in vitro, and they express a subset of erythroid-specific genes at high levels.
Many studies of gene expression have historically been carried out in erythrob-
lasts, and the biogenesis of β-globin mRNA—the most highly expressed transcript
in erythroblasts—was the focus of many seminal studies on the mechanisms of pre-
mRNA splicing.
I isolated nascent, chromatin-associated RNAs from MEL cells before and af-
ter induction of terminal erythroid differentiation and performed long-read se-
quencing on the Pacific Biosciences Sequel platform. Splicing was not accompa-
nied by transcriptional pausing and was detected when RNA polymerase II (Pol
II) was within 75 – 300 nucleotides of 3′ splice sites, often during transcription of
the downstream exon. Interestingly, several hundred introns displayed abundant
splicing intermediates, suggesting that splicing delays can take place between the
two catalytic steps of splicing. Overall, splicing efficiencies were correlated among
introns within the same transcript, and intron retention was associated with inef-
ficient 3′ end cleavage. Remarkably, a thalassemia patient-derived mutation intro-
ducing a cryptic 3′ splice site improves both splicing and 3′ end cleavage of indi-
vidual β-globin transcripts, demonstrating functional coupling between the two
co-transcriptional processes as a determinant of productive gene output.
Thus, I conclude that highly expressed pre-mRNAs in MEL cells are largely
spliced co-transcriptionally, and that the mammalian spliceosome can assemble
and act rapidly on this set of pre-mRNAs. A previously unappreciated level of
cross-talk between splicing and 3′ end cleavage efficiencies is involved in erythroid
development. Together, this work provides a high-resolution description of mam-
malian gene expression and shows that short-read RNA sequencing of bulk RNA
can conceal coordinated behaviours that can only be observed at the level of indi-
vidual nascent transcripts.
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1.1 Eukaryotic Pre-mRNA Splicing
Eukaryotic genes contain intervening sequences—introns—which must be removed
after transcription and before translation of a pre-mRNA to ensure proper gene ex-
pression. Introns are recognized and removed by a multi-megadalton molecular
machine called the spliceosome, which is comprised of five small nuclear RNAs
and hundreds of associated proteins (Papasaikas and Valcarcel, 2016). The spliceo-
some assembles de novo on each intron, recognizing nucleotide sequences called
the 5′ and 3′ splice sites (SS) that demarcate intron boundaries. The spliceosome
then catalyzes two transesterification reactions to excise the intron and ligate the
flanking exons together (Wilkinson et al., 2019).
Decades of biochemistry, genetics, and more recently structural biology, have
shed light on the stunningly complex mechanism of pre-mRNA splicing (Figure
1.1). The spliceosome is not a pre-assembled enzyme, but rather a dynamic com-
ing and going of protein-RNA complexes called small nuclear ribonucleoproteins
(snNRPs). Spliceosome assembly begins with U1 and U2 snRNP binding to the
5′SS and the branchpoint sequence (BPS) of the pre-mRNA substrate respectively.
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A helicase protein then unwinds the helix formed between the 5′SS and U1 small
nuclear RNA (snRNA), and transfers the 5′SS sequence to U6 snRNA, which is as-
sembled in a complex called the tri-snRNP, consisting of U4, U5, and U6 snRNPs.
Next, U1 and U4 snRNPs are released, leaving U2, U5, and U6 snRNPS to perform
the catalytic steps of splicing. After the first transesterification step, the 5′-exon and
lariat intermediates are rearranged to allow for the second step to occur, resulting
in the release of the lariat, and the ligation of the 5′ exon to the 3′ exon. Finally, all
the components of the spliceosome must be disassembled and recycled to prepare
for assembly and splicing of another intron.
In mammalian cells, genes typically encode pre-mRNAs containing 8-10 introns
of variable lengths (ranging from 50 to 500,000 nt), creating a high cellular demand
for spliceosomes relative to other cellular machineries, which only act once per
transcript. Splicing is also a highly-regulated process; it is influenced by environ-
mental factors, developmental cues, and factors in the local pre-messenger RNA
(pre-mRNA) environment, such as RNA secondary structure and RNA-binding
protein occupancy (Baralle and Giudice, 2017; Jeong, 2017; Lin et al., 2016; Pai and
Luca, 2019). Since the 5′SS, 3′SS and branchpoint sequence are rarely exact consen-
sus sequences, additional regulators are thought to explain the correct recognition
of introns. Additionally, trans-acting factors likely play a large role in how constitu-
tive and alternative splice sites are chosen. These working models still largely rely
on in vitro biochemistry and often do not explain changes in alternative splicing
or overall gene expression observed upon experimental perturbation or disease-
associated mutations of splicing factors (Joshi et al., 2017; Manning and Cooper,
2017). Thus, despite detailed knowledge of modulatory factors, the mechanisms














Figure 1.1: Simplified model of the pre-mRNA splicing cycle.
The spliceosome assembles on each intron in pre-mRNA in a step-wise manner. U1,
U2, U4, U5, and U6 snNRPs (coloured ovals) facilitate positioning the pre-mRNA
(top left, grey) in the spliceosome active site as well as carrying out the catalysis of
splicing. Two transesterification reactions (step I and step II, red) result in branch-
ing of the lariat and exon ligation. The final mRNA product is released from the
spliceosome, and the entire complex is disassembled.
3
1.2 Co-transcriptionality
Across species, tissues, and cell types, splicing can occur during pre-mRNA synthe-
sis by Pol II (Custodio and Carmo-Fonseca, 2016; Neugebauer, 2019; Carrocci and
Neugebauer, 2019), meaning that introns can be excised before Pol II terminates
transcription. Thus, spliceosome assembly occurs as the nascent RNA is growing
longer and more diverse in sequence and structure. Spliceosomes may not assem-
ble on all introns at the same time, because promoter-proximal introns are synthe-
sized before promoter-distal introns. Thus, the questions of whether introns are
spliced in the order they are transcribed and how splicing of individual introns
within a given transcript might be coordinated are currently the subject of intense
investigation. Co-transcriptional splicing also demands that the constellation of
splicing factors capable of regulating a splicing event bind the nascent RNA coor-
dinately with the timing imposed by transcription and in a relevant spatial window.
For example, a splicing inhibitor element in a given nascent RNA would only be
influential if it were transcribed before the target intron was removed.
Another issue raised by co-transcriptional RNA processing is how splicing is
coordinated with other pre-mRNA processing steps (Bentley, 2014; Herzel et al.,
2017). In a recent study from the Neugebauer lab in fission yeast (Herzel et al.,
2018), “all or none” splicing of individual nascent transcripts was discovered, where-
in nascent transcripts were more likely than would be expected by chance to con-
tain multiple introns that were either all spliced or all unspliced. This suggested
both positive and negative cooperativity among splicing of neighboring introns.
These transcripts appeared to have opposite fates regarding 3′ end formation: all
spliced transcripts are efficiently cleaved, whereas unspliced transcripts exhibit in-
efficient 3′ end cleavage. Indeed, crosstalk among introns was observed in human
cells at the same time by others (Kim and Abdel-Wahab, 2017; Tilgner et al., 2018).
However, those studies did not explore coupling to 3′ end formation. Cleavage of
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the nascent RNA by the cleavage and polyadenylation machinery at polyA sites
(PAS) releases the RNA from Pol II and the RNA is subsequently polyadenylated
(Kumar et al., 2019). Coupling between splicing and 3′ end cleavage is important,
because uncleaved transcripts are degraded by the nuclear exosome in Schizosac-
charomyces pombe (Herzel et al., 2018; Meola et al., 2016; Zhou et al., 2015). Whether
3′ end cleavage efficiency contributes to gene expression levels in mammalian cells
is currently unknown.
Previous studies from the Neugebauer lab have shown that only a small por-
tion of the downstream exon may be needed for 3′SS identification and splicing
in yeasts (Carrillo Oesterreich et al., 2016; Herzel et al., 2018; Alpert et al., 2020).
Interestingly, altering the rate of Pol II elongation affects splicing outcomes, and
can introduce widespread changes in alternative splicing (Aslanzadeh et al., 2018;
Braberg et al., 2013; Carrillo Oesterreich et al., 2016; de la Mata et al., 2003; Fong
et al., 2014; Ip et al., 2011; Jonkers and Lis, 2015; Schor et al., 2013). Taken together,
these findings suggest that transcription elongation rates may govern the amount
of downstream RNA available for cis regulation at the time that splicing takes place.
This in turn would determine which trans-acting regulatory factors could be re-
cruited to the nascent RNA to modulate splicing. To obtain mechanistic insights
into these processes, we need to understand how mammalian cells—with many
more introns per gene and vastly increased levels of alternative splicing compared
to yeast—coordinate co-transcriptional splicing with transcription elongation.
1.3 Methods for Studying Co-transcriptional Splicing
One method for studying the process of co-transcriptional splicing involves exam-
ining the sequence of nascent RNA directly. Sequencing of nascent RNA reports
two critical pieces of information: the position of RNA Pol II during the process of
5
RNA synthesis (marked by the nascent RNA’s 3′ end, which is present in the cat-
alytic center of Pol II) as well as the sequence of the pre-mRNA substrate acted on
by the spliceosome and its processing status (splicing, 3′ end cleavage, polyadeny-
lation, or modification) (Alpert et al., 2017) (Figure 1.2). Data from nascent RNA se-
quencing also provide unique information on multiple co-transcriptional RNA pro-
cessing steps simultaneously, enabling the identification of coupled reactions. For
example, we and others have observed coordination among intron splicing events
by using long-read sequencing of nascent RNA (Drexler et al., 2020; Herzel et al.,
2018; Reimer et al., 2021; Tilgner et al., 2018). Co-transcriptional RNA folding and
nucleobase modifications are topics of current intense investigation that can also be
analyzed by long-read sequencing (Ke et al., 2017; Liu et al., 2019; Parker et al., 2020;
Saldi et al., 2018). Thus, by performing long-read sequencing on nascent RNA, the
researcher has the opportunity to track both the progression of Pol II elongation by
the 3′ end of the nascent RNA sequence and relate Pol II position to the progression
of RNA processing detected in the internal sequence of the nascent RNA. These ap-
proaches rely on two important advancements: first, the ability to isolate nascent
RNA, and second the maturation of long-read sequencing technology.
1.3.1 Long-Read Sequencing
Advancements in nucleotide sequencing technology now allow for much longer
DNA and RNA molecules to be sequenced. Whereas previous “short-read” Next
Generation Sequencing (NGS) libraries consist of 50-300 nucleotide fragments, new
technologies, termed “long-read” sequencing (LRS), allow DNA and RNA up to
hundreds of thousands of bases in length to be sequenced (van Dijk et al., 2018).
This technology is able to determine the nucleotide sequence of large tracts of ge-
nomic DNA, making it a powerful tool for de novo genome assembly (Sohn and











Figure 1.2: Information gained from nascent RNA long-read sequencing.
Each nascent RNA molecule contains information about its co-transcriptional splic-
ing status—whether intron sequences are present or not (top panel). Additionally,
the 3′ end of each nascent RNA molecule represents the position of Pol II (bottom
panel, dotted arrows), as the RNA end is embedded in the elongating Pol II active
site at the time of isolating the RNA. Long-read sequencing captures all nucleotide
sequence information from 5′ end to 3′ end for each nascent RNA molecule.
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about the transcriptome by revealing the identity of full-length mRNA and non-
coding RNA transcripts from their 5′ to 3′ ends (Carrillo Oesterreich et al., 2016;
Deveson et al., 2018; Hardwick et al., 2019; Herzel et al., 2018; Lagarde et al., 2017;
Singh et al., 2019; Tang et al., 2020). Longer reads inherently contain more infor-
mation, potentially including the unique splicing status, RNA modification status,
transcript start site, and polyA cleavage site of each read. Longer reads are less am-
biguous when trying to interpret patterns of alternative isoform usage, i.e. which
exons are ligated together in the same transcript (Tilgner et al., 2015, 2018; Work-
man et al., 2019). The resulting data thereby characterize the functional genome
more completely than short-read NGS data and reveal novel gene products.
The technology behind long-read sequencing was first described in 2003, where
a DNA polymerase was used to incorporate fluorescent nucleotides and single
molecule sequences could be read out with fluorescent microscopy (Braslavsky
et al., 2003). While this initial report only provided “sequence fingerprints” of 5
base pairs in length, the technology has no theoretical maximum on read length,
and current read lengths upward of 2 million base pairs have been reported (Payne
et al., 2019). Pacific Biosciences and Oxford Nanopore are the leading platforms for
long-read sequencing, and both platforms utilize polymerases for reading sequence
information, although in slightly different manners (Midha et al., 2019). The biggest
advantage of long-read sequencing for RNA is the ability to detect unique isoforms
rather than having to infer isoform usage from smaller junctions. With the excep-
tion of one study (Kim and Abdel-Wahab, 2017), previous methods for sequencing
nascent RNA using short-read sequencing technology have provided information
about the splicing status of a single intron, but the reads are not long enough to
cover multiple introns, let alone an entire nascent RNA from transcription start site
to Pol II active site (Khodor et al., 2011; Tilgner et al., 2012).
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1.3.2 Nascent RNA Isolation
Before the advent of biochemical nascent RNA isolation techniques, nascent RNA
was first observed directly in a preparation of “chromatin spreads” (Miller and
Beatty, 1969). Since nascent RNA makes up such a small fraction of total RNA in
the cell, the first experiments tracking nascent RNA molecules were performed on
radioactively labeled, highly-abundant species, for example β-globin pre-mRNA,
immunoglobin heavy and light chains, and SV40 viral transcripts (Kinniburgh and
Ross, 1979; Lai et al., 1978; Schibler et al., 1978). One important finding that led
to the ability to biochemically fractionate all nascent RNA from cells was that the
ternary complex of Pol II, nascent RNA, and chromatin remains stable even un-
der harsh conditions that compact the chromatin from the surrounding nucleo-
plasm—up to 2 M urea and 0.3 M NaCl (Wuarin and Schibler, 1994). This allowed
chromatin-associated nascent RNA and Pol II to be isolated by relatively low-speed
centrifugation. The protocol detailed in Chapter 2 is based on similar approaches
for subcellular fractionation using chromatin purification that have been described
previously (Pandya-Jones and Black, 2009), and has been adapted previously in the
Neugebauer lab for use in budding and fission yeasts (Carrillo Oesterreich et al.,
2010; Herzel et al., 2018). In particular, I have further modified this protocol to
have a gentler centrifugation speed for collecting nuclei of developing erythrob-
lasts, which have a weaker membrane as they begin the process of enucleation (Pi-
mentel et al., 2016).
Other methods are available for isolating nascent RNA which involve metabolic
labeling of newly-transcribed RNAs with a nucleotide analog such as 4-thiouridine
(Duffy and Simon, 2016; Garibaldi et al., 2017). While there are some drawbacks to
this method, namely difficulty in ensuring unbiased incorporation of the nucleotide
analog and possible effects on RNA processing, this method could be considered
as an alternative to chromatin-associated RNA purification. Metabolic labeling and
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chromatin fractionation are roughly similar in cost and ease of use, however one
should be cautioned against using metabolic labeling specifically if the downstream
application is to detect splicing, since there is some debate as to how 4-thiouridine
incorporation may affect splicing (Testa et al., 1999). Moreover, metabolically la-
beled RNA is not necessarily nascent, i.e. the metabolic label will end up in newly
polyadenylated RNA as well. Therefore, some methods of nascent RNA isolation
use immunoprecipitation of Pol II as a further enrichment step, and this could be
considered if genetic tagging of Pol II is a viable option in your cell type of choice.
However, to date, only one lab has reported using this method in conjunction with
long-read sequencing (Drexler et al., 2020).
1.3.3 Template-Switching Reverse Transcriptase
A key reagent in the protocol described in Chapter 2 is the template-switching re-
verse transcriptase (RT) (Zhu et al., 2001). This enzyme is able to synthesize the first
strand of cDNA from the nascent RNA template using the blunt ligated adapter at
the 3′ end. Then, once the enzyme reaches the 5′ end of the nascent RNA template, it
incorporates several nucleotides through non-templated addition, which act as an
annealing point for the unique template-switching oligo. The RT can then switch
strands and generate the second strand all in the same reaction. Importantly, this
means that the resulting cDNA molecule retains the original 5′ and 3′ ends. This
is extremely informative for analysis of both Pol II position and transcription start
site. The template-switching RT is also more efficient at switching templates in the
presence of a 5′-m7G cap, which is installed on mRNAs after only 23 nucleotides of
transcription (Rasmussen and Lis, 1993), enriching for full-length cDNA molecules
in the final sequencing library (Wulf et al., 2019).
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1.4 Erythropoiesis as a Model System in RNA Biology
Erythropoiesis is the developmental pathway by which red blood cells (RBC)—
specialized hemoglobin-containing cells that deliver oxygen throughout the body—
are produced from hematopoietic stem and progenitor cells (HSPC). Morphologi-
cally, erythropoiesis includes the loss of the cell nucleus and acquisition of a charac-
teristic disk-like shape (Figure 1.3). Early molecular biologists identified erythropoiesis-
associated gene expression patterns such that the globin genes are among the best
understood eukaryotic genes. β-globin was among the first proteins to be sequenced
and was the first protein to be characterized structurally by using x-ray crystallog-
raphy. The β-globin gene and mRNA were also among the first to be cloned. These
advances facilitated early discoveries in gene regulation, such as the transcriptional
control of globin genes by long-range enhancer and repressor elements present in
the locus control region (Grosveld et al., 1987). This system of transcriptional reg-
ulation is currently being exploited to discover how chromosomal regions interact
and how chromatin looping might become a therapeutic target in diseases of RBCs
(Krivega and Dean, 2016; Yu and Ren, 2017).
RNA biology is an area in which erythropoiesis, globin gene regulation, and
disease mutations have led to fundamental discoveries. Globin pre-mRNA, which
contains two introns, was an early model substrate for the investigation of splicing
mechanisms (Konkel et al., 1978; Lerner et al., 1980), and mutations in globin genes
at the 5′ and 3′ splice sites proved to be the cause of various forms of thalassemias
(Maquat et al., 1980). Thalassemias are hemoglobin deficiencies resulting from
aberrant globin expression. Some thalassemia mutations cause intron retention (IR)
and lead to nonsense-mediated decay (NMD), a major gene regulatory mechanism
that degrades mRNA transcripts containing premature termination codons (PTC)
present in retained introns (Chang et al., 1979; Maquat et al., 1981). Finally, other
























Figure 1.3: Changes in gene expression and splicing occur during terminal
erythroid differentiation.
Erythropoiesis is characterized by changes in cell morphology, including nuclear
size, color (due to hemoglobinization), and chromatin condensation, which are
coordinated with changes in gene expression. During terminal erythroid dif-
ferentiation, cells progress from proerythroblasts (PRO), to basophilic erythrob-
lasts (EARLY and LATE BASO), to polychromatophilic erythroblasts (POLY), to
orthrochromatic erythroblasts (ORTHO), before enucleation to become red blood
cells (RBCs) (also called reticulocytes). In human erythroblasts, a subset of genes
is downregulated — some top associated Gene Ontology terms are shown to the
right (purple line) — while a subset of genes is concurrently upregulated (green
line). Changes in splicing occur in the later stages of erythropoiesis (mostly from
late baso to ortho), including increased alternative splice site usage and intron re-
tention.
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age and polyadenylation of β-globin mRNA, showing the importance of this RNA
processing mechanism in health and disease.
1.4.1 Transcriptome-Wide Changes During Erythropoiesis
During erythropoiesis, each cell division is coincident with major changes in gene
expression, resulting in daughter cells that are morphologically and transcription-
ally distinct from the mother cell (An et al., 2015). Transcriptome-wide profiling us-
ing RNA sequencing (RNA-seq) has allowed unbiased dissection of changes that
occur along this developmental pathway (An et al., 2014). The greatest number
of changes in gene expression in human erythroblasts — either upregulation or
downregulation — occurr between the late basophilic to polychromatic and poly-
chromatic to orthochromatic stages, where roughly equal numbers of genes are up-
regulated as are downregulated. These transcripts are enriched for different anno-
tated functions reflecting cellular events in the differentiation process (Figure 1.3),
emphasizing the changing transcriptional landscape that underlies massive globin
gene expression in terminal stages of erythroid development. In contrast, when
mouse erythroblasts are analyzed in the same manner, the overwhelming major-
ity of genes, including key transcription factors, are downregulated. The cause
for species-specific differences in transcriptome changes is not immediately clear
but likely reflects distinct properties of human and mouse erythrocytes, including
differences in size, life span, oxygen-carrying capacity, and metabolism (An et al.,
2015). An analysis of chromatin accessibility, histone modifications, and transcrip-
tion factor binding in a mouse embryonic stem cell model of hematopoiesis has
revealed a complex regulatory network that drives changes in the transcriptome
during differentiation (Goode et al., 2016). It remains to be seen whether these
mechanisms differ between human and mouse erythroblasts, explaining the pro-
nounced differences in transcriptomes.
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1.4.2 Splicing Regulation in Normal Erythropoiesis
Splicing can contribute to the regulation of transcript levels by activating cellular
programs, such as NMD, to reduce transcript levels. Moreover, alternative splicing
leads to the expression of different transcripts and protein products from the same
gene (Papasaikas and Valcarcel, 2016). How does splicing regulation contribute to
transcriptome diversity in erythroid development? Early work using microarrays
to detect changes in splicing during erythropoiesis found altered splicing in known
trans-acting splicing factors (for example, SNRP70, HRNPLL, and MBNL2), which
are RNA-binding proteins that regulate how the spliceosome assembles on pre-
mRNA and how different 5′ and 3′SSs are chosen (Yamamoto et al., 2009). This sug-
gested a regulatory feedback loop, whereby changes in splicing factors could affect
the splicing of many downstream genes necessary for development. Subsequent
work has focused on identifying stage-specific changes in splicing transcriptome-
wide by using RNA-seq, a less biased approach that does not rely on known in-
tron–exon boundaries (An et al., 2015). In addition, mapping the gene expression
networks governed by splicing in erythroid differentiation has aided identification
of the functional significance of splicing regulation (Conboy, 2017).
One of the first and best-characterized examples of alternative splicing in ery-
thropoiesis is the stage-specific inclusion of exon 16 of the 4.1R protein-encoding
gene, which is crucial for erythrocyte membrane integrity (Yamamoto et al., 2009;
Hou et al., 2002). Changes in expression levels and specific binding of the hnRNP
A/B protein affect this developmental switch (Hou et al., 2002). Since then, al-
ternative splicing has emerged as a more widespread phenomenon (Baralle and
Giudice, 2017; Cheng et al., 2014; Wong et al., 2018). The muscleblind-like protein
1 (MBNL1) is a sequence-specific splicing factor that undergoes extensive alterna-
tive splicing during differentiation (Cheng et al., 2014). Cheng et al. showed that
a specific Mbnl1 isoform which includes the alternative exon 5 accumulates in the
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nucleus in later stages of erythroid differentiation (Cheng et al., 2014). The inclu-
sion Mbnl1 isoform is responsible for regulating the splicing of downstream genes
important for erythroid differentiation, as knockdown of the Mbnl1 inclusion iso-
form alone blocked differentiation and caused defects in proliferation. Mirroring
the previous findings observed by microarrays, Pimentel et al. report a program of
highly dynamic alternative isoform switching in late-stage human erythroblasts us-
ing RNA-seq (Pimentel et al., 2014). An increase in steady-state levels of transcripts
containing PTCs, which likely trigger NMD of these transcripts, was observed in
the later stages of differentiation, suggesting that alternative splicing coupled to
NMD may be a novel, stage-specific gene regulatory mechanism.
1.4.3 Intron Retention During Hematopoiesis
Intron retention (IR) is a class of alternative splicing wherein an intron is not re-
moved by the spliceosome, potentially introducing PTCs and targeting the tran-
script for NMD. Alternatively, it is possible that certain intron-retained transcripts
remain in the nucleus and undergo splicing with delayed kinetics (Boutz et al., 2015;
Bhatt et al., 2012; Boothby et al., 2013; Mauger et al., 2016). IR was only recently rec-
ognized as a widespread occurrence (Wong et al., 2013; Braunschweig et al., 2014),
and developing erythroid cells exhibit robust IR. Pimentel et al. showed that late
human erythroblasts accumulate hundreds of transcripts containing retained in-
trons and that the formation of these IR transcripts are enriched for splicing factors
and iron-homeostasis factors (Pimentel et al., 2016). These results were corrobo-
rated at the single-cell level in human immortalized myelogenous leukemia K562
cells (Abdelmoez et al., 2018). The top three categories of nuclear IR transcripts
by gene ontology analysis were RNA metabolism, RNA splicing, and the C com-
plex spliceosome. The retained introns detected in late human erythroblasts were
more likely to be found next to alternative exons that contained PTCs (Pimentel
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et al., 2016), in line with previous studies suggesting that IR followed by NMD is
an important mechanism that regulates levels of splicing factors (Ni et al., 2007).
How is IR triggered during erythropoiesis? Key insights are emerging from
studies of transcripts encoding the important core splicing factor SF3B1. SF3B1 ex-
pression is also subject to IR during erythroid differentiation, and work suggests
that SF3B1 regulation by IR may constitute a regulatory hub leading to the down-
regulation of transcripts encoding other splicing factors (Pimentel et al., 2016). In-
deed, a series of highly conserved cryptic SSs were identified for their activity
in promoting IR in SF3B1 transcripts (Parra et al., 2018). The identified intronic
sequences are sufficient to promote IR in SF3B1 and can also promote retention
when inserted into other introns. The cryptic exons generated by these SSs are
proposed to act as splicing decoys, sequestering components of the spliceosome
and ultimately preventing productive splicing by blocking the appropriate cross-
intron interactions needed to define the intron for splicing. Alternatively, reduced
levels of SF3B1 might preferentially affect splicing efficiencies or the half-lives of
pre-mRNAs/mRNAs encoding splicing factors or both. Although we presume
that most of these instances reflect the downregulation of IR transcripts, the pos-
sibility that certain splicing events are delayed remains. Interestingly, delaying
gene expression through IR is physiologically relevant in other cell types, including
developing spermatocytes, neuronal cells, platelets, granulocytes, and stimulated
macrophages (Wong et al., 2013; Yap et al., 2012; Edwards et al., 2016; Denis et al.,
2005; Naro et al., 2017). In the case of erythroid differentiation, how introns are re-
tained in a seemingly stage-specific and cell type-specific way remains to be fully
understood.
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1.4.4 Misregulation of Splicing in β-Thalassemia
Misregulation of splicing underlies a growing number of human diseases (Urban-
ski et al., 2018; Dvinge et al., 2016; Scotti and Swanson, 2016; Faustino and Cooper,
2003). Generally, mutations either in cis or in trans can affect splicing outcomes. Cis
mutations may disrupt the intrinsic sequences that demarcate SSs in a transcript (5′
and 3′SSs). In contrast, mutations in any member of the core spliceosome machin-
ery can produce splicing defects in trans, causeing deleterious effects for a large
number of downstream splicing substrates. Both types of splicing defects have
been characterized in the erythroid lineage (Hahn et al., 2015).
β-thalassemias are a family of disorders defined by mutations in the β-globin
gene, causing a reduction of β-globin mRNA, insufficient hemoglobinization of ma-
turing RBCs, and anemia (Thein, 2013). β-thalassemia is one of the most prevalent
diseases caused by somatic mutations worldwide, yet currently the only available
curative treatment is an allogenic transplant of HSPCs from a matched donor. This
option is unavailable for many patients because of the cost of treatment and lim-
ited availability of matched donors. Although we possess a quite thorough under-
standing of the molecular basis and pathophysiology of this disease, better treat-
ments are sorely needed. Many β-thalassemia patients are dependent on trans-
fusions from blood donors to maintain proper levels of healthy, circulating RBCs.
However, this therapy often leads to complications related to iron overload, includ-
ing organ damage. The majority of β-globin alleles that cause thalassemia contain
point mutations (Figure 1.4). These mutations can affect virtually any step in the
correct expression of β-globin mRNA from transcription initiation (Figure 1.4 A),
to splicing (Figure 1.4 B, C), to 3′ end cleavage and polyadenylation (Figure 1.4 E).
Because of this, β-thalassemia is an attractive target for applying genome-editing
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Figure 1.4: Single-nucleotide mutations in key regulatory regions of the
β-globin gene disrupt expression in β-thalassemia.
Point mutations in varying regions of the β-globin gene are shown schemati-
cally, and the frequencies of these mutations listed in the HbVar database (http:
//globin.bx.psu.edu/hbvar/menu.html) are shown in brackets at the left. Gene re-
gions are divided into (A) promoter, (B) splice sites, (C) other intronic regions, (D)
exons, and (E) polyadenylation site. These mutations (red X’s) have varying effects,
illustrated below each example, but all lead to decreased or abolished expression of
the β-globin transcript. AS, alternative splicing; NMD, nonsense-mediated decay;
PTC, premature termination codon.
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1.5 Summary
Erythropoiesis provides an excellent model in which to study RNA splicing in both
healthy and diseased states. Mutations affecting genes important for mature RBC
function (for example, β-globin) have revealed aberrant splicing which leads to
hindered erythropoiesis, often in unexpected ways. In the following chapters, I
report an analysis of nascent RNA transcription and splicing in murine erythroid
leukemia (MEL) cells undergoing erythroid differentiation, a developmental pro-
gram that exhibits well-known, drastic changes in gene expression (An et al., 2014;
Reimer and Neugebauer, 2018). I have employed two single-molecule sequenc-
ing approaches to directly measure co-transcriptional splicing of nascent RNA:
(i) Long-Read Sequencing (LRS), which enables genome-wide analysis of splicing
with respect to Pol II position and (ii) Precision Run-On Sequencing (PRO-seq),
enabling the assessment of Pol II density at these sites. I have rigorously deter-
mined the spatial window in which co-transcriptional splicing occurs and defined
co-transcriptional splicing efficiency for thousands of mouse introns, Pol II elonga-
tion behavior across splice junctions, and the effects of efficient co-transcriptional
splicing on 3′ end cleavage. Specifically, a patient-derived β-thalassemia allele with
a single point mutation at the 3′SS shows an increase in both co-transcriptional
splicing efficency and 3′ end cleavage efficiency compared to the wild type allele.
These findings identify the pre-mRNA substrates of splicing and show that splicing
of multiple introns within individual transcripts is coordinated with 3′ end cleav-
age. In particular, the demonstration of highly efficient splicing in the absence of





2.1 Preparation of Nascent RNA for Long-Read
Sequencing
In this protocol, chromatin-associated RNAis purified from murine erythroleukemia
(MEL) cells by first performing subcellular fractionation to physically separate chro-
matin (Basic Protocol 1: Subcellular Fractionation). Then, nascent RNA is enriched
by depleting polyadenylated RNA(polyA+ RNA) and ribosomal RNA(rRNA), and
nascent RNA 3′ ends are ligated to a unique adapter to retain the position of the Pol
II active site when RNA was isolated (Basic Protocol 2: Nascent RNA Isolation and
Adapter Ligation). Finally, a template-switching reverse transcriptase is used to
generate a full-length cDNA copy of the nascent RNA. Minimal polymerase chain
reaction (PCR) cycles are used to amplify a cDNA library before long-read sequenc-




Basic Protocol 1: Subcellular Fractionation









Basic Protocol 3: cDNA Amplicon Preparation







Basic Protocol 2: Nascent RNA Isolation and Adapter Ligation
polyA and rRNA depletionchromatin-associated RNA adpater ligation
nascent




Attaining enough nascent RNA from cells is critical for the success of this protocol.
The limiting reagent is nascent RNA that has been depleted of polyA+ RNA and
rRNA, of which you need 600 ng for the downstream adapter ligation reaction.
However, the polyA+ depletion and rRNA depletion steps can have a fairly low
yield. The yield for polyA+ depletion is often approximately 70%, and the yield
for rRNA depletion can be 5-10%. Thus, I suggest not continuing to Basic Protocol
2 unless you have at least a total of 14 µg of chromatin-associated RNA at the end of
Basic Protocol 1. In my experience, 20 million MEL cells yield approximately 5 µg of
chromatin-associated RNA, so fractionating 3 x 20 M cells in parallel and combin-
ing the chromatin-associated RNA after isolating from Trizol should be sufficient.
However, the yield of nascent RNA is variable between cell types, so this should
be monitored closely. The quality of the nascent RNA is also extremely important,
as this will directly affect the quality of the downstream cDNA library. The RNA
260/280 and 260/230 values should be monitored by Nanodrop where mentioned,
and the RNA can be quickly inspected by running it on an agarose gel (Figure 2.3).
In addition to after collecting the chromatin-associated RNA (Basic Protocol 2, step
22), the user could run the RNA on an agarose gel after polyA+ depletion if they
suspected RNA degradation based on the Nanodrop reading.
Subcellular fractionation (Basic Protocol 1) should be optimized for each cell
type, and success should be monitored by Western blotting. A successful fractiona-
tion is one where Pol II remains in the chromatin fraction, and the cytoplasmic and
nucleoplasmic markers are strongly depleted from the chromatin fraction (Figure
2.2). When attempting this protocol with another cell type, the main step that will
need to be optimized is the subcellular fractionation. Since this protocol is written
for MEL cells which are erythroid cells, the centrifugation step to isolate nuclei has
been decreased to prevent their slightly weaker nuclear membranes from burst-
22
ing during centrifugation (Basic Protocol 1, step 7). For most other cell types, this
centrifugation speed should be gradually increased and the nuclei and cytoplasm
fractions should be observed under a light microscope to observe that nuclei are
intact. If cells that grow in monolayer are used, then they should be rinsed quickly
with 1X PBS + 1 mM EDTA on the plate before using a cell scraper to harvest them
(in place of Basic Protocol 1, steps 1 and 2). The yield of chromatin-associated RNA
is variable between different cell types, so this should be monitored closely, and the
number of input cells should be adjusted so that the user yields a total of approx-
imately 14 µg of chromatin-associated RNA at the end of Basic Protocol 2, RNA
Isolation. However, the subcellular fractionation tends to work best with no more
than 20 million cells in the tube, so adjust the number of tubes that are combined
rather than adjusting the number of cells in the tube.
Multiple samples can be sequenced on the same flow cell if a barcode is in-
troduced during the reverse transcription step. See Table 5.1 for a list of barcode
sequences that can be inserted in the custom RT primer used for this step. The bar-
coded RT primer can be ordered from any oligonucleotide synthesis company but
should be ordered PAGE-purified.
During the PCR cycle number optimization, the goal is to use as few rounds
of PCR amplification as possible to minimize amplification bias in the library. A
cycle number of 11-15 is usually chosen, and anything more than 18 cycles should




Before beginning, the user should have MEL cells actively growing. These cells
grow in suspension in DMEM + GlutaMAX (Thermo Fischer Scientific, cat. no.
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10569-010) supplemented with Fetal Bovine Serum (Thermo Fischer Scientific, cat.
no. 26140) and Penicillin-Streptomycin (Thermo Fischer Scientific, cat. no. 15140122)
in non-treated T-25 flasks (Thermo Fischer Scientific, cat. no. 169900). For more in-
formation on MEL cell growth and induction, see (Antoniou, 1991). Cells should be
counted with a hemocytometer to determine their density, and the culture density
should be recorded for several days before beginning the protocol to ensure con-
sistent doubling is occurring. Cultures should be diluted back to 5 x 104 cells/ml
once they reach a density of 1-2 x 106 cells/ml. Once cells are in active growth, they
should double in number approximately every 12 hours. At this point, the cells are
ready to use for this protocol.
Minimum Cell Input
For one replicate to be prepared using this protocol, approximately 80 million cells
are needed as input: 60 million cells will be used to isolate nascent RNA and 20
million cells will be used to test the success of subcellular fractionation by West-
ern blot. This number of cells can often be gathered from 4 flasks of cells, each
containing 20 million cells (10 ml culture at a density of 2 x 106 cells/ml).
2.1.3 Basic Protocol 1: Subcellular Fractionation
Here, the user will perform subcellular fractionation to separate the chromatin from
the nucleoplasm and cytoplasm of mammalian cells. This approach is based on the
evidence that under harsh conditions that lyse the nuclear membrane and dissoci-
ate any non-specifically bound RNA, the ternary complex of Pol II, chromatin, and
nascent RNA remains intact and precipitates from solution (Wuarin and Schibler,
1994). After subcellular fractionation, the user will collect a sample from each frac-
tion and check that characteristic marker proteins are in each fraction by Western
blot. If the fractionation is successful, the user will then continue to collect nascent
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RNA from the chromatin fraction.
Care should be taken to minimize time in between steps, especially after cell
lysis and nuclear lysis steps. In order to monitor the success of fractionation, a
minimum of two samples should be fractionated in parallel. For one sample, each
fraction is kept for use in Western blotting. For the second sample, the chromatin
fraction is used to isolate RNA. All buffers used from the point of cell lysis to pel-
leting the chromatin contain α-amanitin, an inhibitor of Pol II, which prevents Pol
II from elongating and allows the position of Pol II to be accurately captured. Note
that buffers containing α-amanitin, a potent toxin, should be handled with extreme
care, and all buffer waste should be disposed of properly. All buffers should be
freshly prepared and chilled on ice before beginning. This protocol is specific for
murine erythroleukemia cells but has been easily adapted to other mammalian cell
types in our lab. This protocol works best on freshly harvested, not frozen, cells.
Materials
Reagents and Chemicals
• MEL cells in active growth
• 1X PBS (Americanbio, cat. no. AB11072-01000) + 1 mM EDTA (Americanbio,
cat. no. AB00502-00100)
• Cell lysis buffer (see recipe in Reagents and Solutions, page 54)
• Sucrose buffer (see recipe in Reagents and Solutions, page 54)
• Nuclear resuspension buffer (see recipe in Reagents and Solutions, page 54)
• Nuclear lysis buffer (see recipe in Reagents and Solutions, page 54)
• Trizol Reagent (Thermo Fischer Scientific, cat. no. 15596026)
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• NuPAGE 4X LDS Sample Buffer (Thermo Fischer Scientific, cat. no. NP0007)
• 4-12% Bis-Tris gel (Thermo Fischer Scientific, cat. no. NP0322PK2, or poured
in house)
• Precision Plus Protein Dual Color Standards (BioRad, cat. no. 1610374)
• NuPAGE MOPS-SDS running buffer (Thermo Fischer Scientific, cat. no. NP0001)
• NuPAGE transfer buffer (Thermo Fischer Scientific, cat. no. NP0006)
• 5% bovine serum albumin (BSA) in 0.1% TBS-T (Tris-buffered saline, 0.1%
Tween 20)
• 0.1% TBS-T
• 3% BSA in 0.1% TBS-T
• anti-GAPDH antibody (Santa Cruz, cat. no. sc-25778)
• anti-U1-70K (CB7) antibody (hybridoma supernatant available upon request)
• anti-NXF1 TAP N-19 antibody (Santa Cruz, cat. no. sc-17310)
• anti-Pol II (4H8) antibody (Santa Cruz, cat. no. sc-47701)
• Mouse IgG, HRP-linked whole Ab (Cytiva, cat. no. NA931)
• Rabbit IgG, HRP-linked whole Ab (Cytiva, cat. no. NA934)
• Pierce ECL Western blotting substrate (Thermo Scientific, cat. no. 32106)




• Wide bore P1000 pipette tips (VWR, cat. no. 89049-166)
• Refrigerated microcentrifuge
• 1.5-ml tubes (Dot Scientific, cat. no. RN1700-GMT)
• vortex
• Sonicator (Branson, fitted with a 2 mm microtip probe)
• Heat block at 95°C




1. Count actively growing MEL cells using a hemocytometer. For each replicate,
aliquot 20 million cells from each flask into a 15-ml conical tube, for a total of
4 tubes with 80 million cells. Centrifuge all tubes 5 min at 1,500 revolutions
per minute (rpm), room temperature.
Note: As mentioned in the strategic planning section, three of the tubes will be used
for nascent RNA isolation, and one tube will be used for confirming the success of
subcellular fractionation by western blot. Perform all steps through step 15 on all
15-ml tubes simultaneously, each with 20 million cells.
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2. Gently resuspend the cell pellet in 1 ml ice-cold PBS + 1 mM EDTA by pipet-
ting up and down approximately 5 times while using a wide bore P1000
pipette tip.
3. Centrifuge 5 min at 1,500 rpm, 4°C.
4. Gently resuspend the cell pellet in 250 µl cell lysis buffer.
Note: Pipette up and down while using a wide bore P1000 pipette tip just until cells
are in a turbid suspension, approximately 10 times up and down. Some small clumps
of cells are OK.
5. Incubate 5 min on ice.
6. Add 500 µl of sucrose buffer to a new 1.5-ml tube and carefully layer the cell
lysate on top.
7. Centrifuge the tube 10 min at 2,000 rpm, 4°C in a microcentrifuge.
8. Aspirate the supernatant (this is the cytoplasmic fraction), and transfer to a
new 1.5-ml tube. Set aside on ice.
Note: Be careful not to disturb the pellet at the bottom of the tube.
9. Rinse the white nuclear pellet with 500 µl of ice-cold PBS + 1mM EDTA by
pipetting the solution down the side of the tube to avoid disturbing the pellet,
then aspirating the solution completely.
10. Resuspend the nuclear pellet in 100µl of nuclear resuspension buffer by pipet-
ting the buffer on top of the pellet, then gently flicking the closed tube.
Note: It is easiest to drag the tube across a bumpy surface, such as across the holes of
a tube rack several times. The nuclei should easily resuspend into a somewhat turbid
suspension.
11. Add 100 µl of nuclear lysis buffer, then vortex for 5 seconds.
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12. Incubate 3 min on ice.
13. Centrifuge for 2 min at 14,000 rpm, 4°C.
14. Aspirate the supernatant (this is the nucleoplasmic fraction), and transfer to
a new 1.5-ml tube. Set aside on ice.
15. Rinse the chromatin pellet left in the tube with 500 µl of ice-cold PBS/1 mM
EDTA.
Note: Make sure to remove as much supernatant as possible to remove nucleoplasmic
RNA contamination in chromatin-associated RNA. The chromatin pellet should be
very stable.
16. Add 100 µl ice-cold PBS to one tube (this is the chromatin fraction for Western
blot), then set aside on ice. To the other three tubes, add 100 µl ice-cold PBS
and 300 µl Trizol, then vortex briefly just until the pellet releases from the
bottom of the tube.
Note: The chromatin pellet should be very insoluble. It will not dissolve in Trizol.
17. Either transfer the three tubes containing Trizol to -80°C for up to 1 month or
continue immediately to nascent RNA isolation (Basic Protocol 2).
Western Blot
18. Place the 1.5-ml tubes containing the cytoplasmic fraction (from step 8), nu-
cleoplasm fraction (from step 14), and chromatin fraction (from step 16) on
ice. Adjust the volume in each tube with PBS so that the three fractions con-
tain an approximately equal volume.
Note: The cytoplasmic fraction should be the largest, approximately 750 µl.
19. For the nucleoplasm and chromatin fractions, sonicate on ice at 30% ampli-
tude for 1 min total, with 10 seconds on followed by 20 seconds off.
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20. Centrifuge all three tubes (cytoplasm, nucleoplasm, and chromatin) for 10
min at 14,000 rpm, 4°C.
21. Aliquot 20 µl of the supernatant from each tube into a new 1.5-ml tube.
22. Add 5 µl 4X LDS sample buffer to each tube. Mix by pipetting up and down.
Note: Try to avoid creating bubbles when pipetting up and down by keeping the tip
submerged.
23. Incubate 5 min at 95°C.
24. Centrifuge 1 min at 14,000 rpm, room temperature.
25. Load cytoplasm, nucleoplasm, and chromatin samples on a 4-12% Bis-Tris gel
alongside 10 µl of prestained ladder. Run the gel in 1X MOPS-SDS running
buffer at 180 V until the dye front is just off the bottom of the gel, approxi-
mately 50 minutes.
Note: Aim to load the prestained ladder in the outermost two lanes to use as a guide
for cutting the membrane later. For more details on SDS gel electrophoresis, see (Gal-
lagher, 2012).
26. Transfer to a 0.2 µm nitrocellulose membrane in 1X NuPAGE transfer buffer
for 2 h at 30 V in a cold room at 4°C.
Note: For more details on Immunoblotting, see (Ni et al., 2017).
27. Rinse the nitrocellulose membrane briefly in distilled water.
28. Block the membrane in 5% BSA in 0.1% TBS-T overnight in a cold room at 4°C
on a nutator.
Note: Incubate the membrane in a closed container to prevent evaporation, and make
sure to add enough solution to cover the membrane completely.
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29. Rinse the membrane at least 1 hour in 0.1% TBS-T at room temperature in a
nutator.
30. Cut the membrane using a sterile blade and a hard flat edge at the 100 kDa and
50 kDa ladder marks to separate the membrane into three pieces. Incubate
the membranes with primary antibodies listed in Table 2.1 in 3% BSA in 0.1%
TBS-T for at least 1 hour at room temperature: incubate the top portion of the
blot with the α-Pol II 4H8 antibody, the middle portion of the blot with the
α-U1-70K antibody, and the bottom portion of the blot with the α-GAPDH
antibody. After incubation, rinse at least 3 times for 10 minutes each with
fresh 0.1% TBS-T in a nutator.
Note: The antibody concentration and time for incubation will need to be optimized
for antibodies for other cell types or antigens. Note that I propose an alternative
marker for the nucleoplasm, NXF1, as U1-70K does not work well in all cell types. I
typically use antibody dilutions of 1:2,000 for α-Pol II 4H8, 1:2,000 for α-GAPDH,
and 1:5 for α-U1-70K.
Table 2.1: Primary antibodies for verification of subcellular fractionation.
Antibody Localization Running Size Source Organism
α-GAPDH cytoplasm 37 kDa rabbit
α-U1-70K nucleoplasm 70 kDa mouse
α-NXF1 nucleoplasm 70 kDa mouse
α-Pol II (4H8) chromatin 240 kDa mouse
31. Incubate the membranes with secondary antibodies in 3% BSA in 0.1% TBS-T
for at least 1 hour at room temperature: use α-rabbit HRP for the GAPDH
membrane, and α-mouse HRP for the U1-70K and Pol II 4H8 membranes.
Note: I typically use antibody dilutions of 1:10,000 for α-rabbit HRP, and 1:8,000
for α-mouse HRP.
32. Rinse the membrane a final 4 times for at least 10 minutes each in fresh 0.1%
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TBS-T at room temperature in a nutator after secondary antibody incubation.
33. Cover the membrane in approximately 1 ml prepared ECL Western blotting
substrate for approximately 60 seconds and expose the membrane to film or






Figure 2.2: Western blot after successful subcellular fractionation of MEL cells.
Cytoplasm (CYT), nucleoplasm (NPL), and chromatin (CHR) fractions are loaded
from left to right. Primary antibodies for each blot are shown to the right; GAPDH
is a marker for the cytoplasm, U1-70K is a marker for the nucleoplasm, and Pol II
4HD is a marker for RNA Pol II, which should be in the chromatin fraction.
2.1.4 Basic Protocol 2: Nascent RNA Isolation and Adapter
Ligation
Nascent RNA refers to RNA which is being actively synthesized by Pol II. While
subcellular fractionation enriches for RNA that is physically bound to the ternary
complex of Pol II on chromatin, further purification is needed to remove contam-
inating mRNA (i.e. not nascent) and rRNA. In this protocol, ribosomal RNA and
chromatin-associated polyadenylated RNAare depleted to enrich for nascent RNA.
While a number of alternative methods are commercially available for both of these
procedures, in my experience, kits with complementary oligos conjugated to mag-
netic beads provide the fastest and most reliable approach for both methods, and
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that approach is described here. After that process, a DNA adapter which is neces-
sary for priming reverse transcription in the downstream protocol is blunt ligated
to the 3′ end of each nascent RNA. This adapter sequence is used in data analysis




• Chromatin-associated RNA (from Basic Protocol 1 step 17)
• Chloroform
• 100% ethanol, room temperature
• RNeasy Mini kit (Qiagen, cat. no. 74104)
• RNase-Free DNase Set (Qiagen, cat. no. 79254)
• DynaBeads mRNA DIRECT Micro Purification kit (Thermo Fischer Scientific,
cat. no. 61021)
• UltraPure Glycogen (Thermo Fischer Scientific, cat. no. 10814010)
• 3 M sodium acetate
• 100% ethanol, ice-cold
• 70% ethanol, ice-cold
• 2X Novex Sample Buffer (Thermo Fischer Scientific, cat. no. LC6876)
• DNA Clean and Concentrator-5 kit (Zymo Research, cat. no. D4013)
• RiboMinus™Eukaryote System v2 (Thermo Fischer Scientific, cat. no. A15026)
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• TAE buffer (40 mM Tris·HCl, 20 mM acetic acid, 1 mM EDTA pH 8.0)
• Agarose (Sigma, cat. no. A9539)
• Lonza Gelstar (Thermo Fischer Scientific, cat. no. 50535)
• GeneRuler 1 kb Plus DNA ladder (Thermo Fischer Scientific, cat. no. SM1331)
• DNA adapter (/5rApp/NNNNNCTGTAGGCACCATCAAT/3ddC/)





• 2-ml tube (Dot Scientific, cat. no. RN2000-GMT)
• 1.5-ml tubes (Dot Scientific, cat. no. RN1700-GMT)
• Nanodrop
• UV gel imaging system
• Magnetic 1.5-ml tube rack
• Heat block at 70°C
• Heat block at 37°C
• Heat block at 65°C





1. Thaw three tubes with chromatin pellets frozen in Trizol (from Basic Protocol
1, step 17) at room temperature just until samples are liquid. Vortex briefly to
mix. If samples were not frozen, proceed immediately to the next step.
Note: For MEL cells, you should plan to isolate nascent RNA from at least 3 chro-
matin fraction pellets (as described in the Strategic Planning section). You will isolate
RNA from each of the three (or more) tubes separately, then the RNA will be com-
bined before the polyA + depletion. Perform all steps through step 21 on all tubes
simultaneously.
2. Incubate samples at 50°C for 10 mins with shaking at 1,400 rpm in Ther-
momixer.
Note: This aids in releasing RNA from the insoluble chromatin and improves the
yield of purified RNA.
3. Add 60 µl chloroform to each tube. Vortex thoroughly (at least 30 seconds).
Note: Chloroform should be used in a fume hood. Make sure the tube lid is closed
securely before vortexing, for example by wrapping the lid with parafilm, as Trizol is
caustic.
4. Incubate 2 min at room temperature.
5. Centrifuge 15 min at 14,000 rpm, 4°C.
6. Transfer the clear upper aqueous phase to a new labeled 2 ml tube. The aque-
ous phase should be about 250 µl.
Note: Make sure to avoid carrying over any interphase. Using a smaller pipette tip
(P200) in multiple aliquots is easier than using a larger tip.
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7. Add 3.5 volumes of RLT buffer (from RNeasy Mini kit) to the tube, then mix
by vortexing briefly.
Note: For example, if the aqueous phase is 250 µl, add 875 µl RLT buffer.
8. Add 2.5 volumes of room temperature 100% ethanol to the tube. Mix well
by pipetting up and down; do not centrifuge. Spin the tube down briefly
(approximately 5 seconds) to collect drops from the lid.
9. Transfer the sample, up to 700 µl at a time, to an RNeasy Mini spin column in
a collection tube.
10. Centrifuge for 15 seconds at 14,000 rpm, room temperature. Discard flow-
through and repeat this step as necessary to pass the entire sample through
the column.
11. Add 350 µl of buffer RW1 (from RNeasy Mini kit) to the RNeasy spin column,
centrifuge as in step 10, and discard flow-through.
12. For each sample, prepare 80 µl of “DNAse I incubation mix” by adding 10 µl
of DNase I stock solution and 70 µl of Buffer RDD (both from the RNase-free
DNase kit) to a new 1.5-ml tube.
Note: Make a master mix here for as many tubes as you have.
13. Mix the DNAse I incubation mix by gently inverting the tube end over end
several times. Centrifuge briefly to collect drops from the lid.
Note: Do not vortex to mix!
14. Add the DNase I incubation mix (80 µl) directly to the RNeasy Mini spin col-
umn membrane.
15. Incubate 15 min at room temperature.
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16. Add 350 µl of Buffer RW1 to the spin column, centrifuge as in step 10, and
discard the flow-through.
17. Add 500 µl of Buffer RPE (from RNeasy Mini kit) to the spin column, cen-
trifuge as in step 10, and discard the flow-through.
18. Add 500 µl of Buffer RPE to the spin column, centrifuge 2 min at 14,000 rpm
at room temperature, and discard the flow-through.
19. Carefully remove the spin column from the collection tube and transfer the
column to a new 1.5-ml tube.
20. Add 30 µl of RNase-free water directly to the center of the column membrane.
Centrifuge for 1 min at 10,000 rpm at room temperature to elute the RNA.
21. Measure the concentration of eluted RNA by Nanodrop. Measure the con-
centration of each sample separately, and if the 260/280 and 260/230 values
are acceptable, combine the replicates for each sample into one 1.5-ml tube.
Note: Users should expect a concentration of 150-200 ng/µl with a 260/280 value
around 2.0, and a 260/230 value around 2.1. Note that a minimum of 10µg of nascent
RNA is recommended after pooling and before continuing to polyA+ depletion.
22. Run 250-500 ng of each pooled nascent RNA sample on a 1% TAE agarose gel
to confirm the integrity of the RNA. See Figure 2.3 for an example of intact
nascent RNA.
(a) Aliquot the nascent RNA into a new 1.5-ml tube. Adjust the volume to
5 µl with sterile water.
(b) Add 5 µl 2X Novex Sample Buffer to the 1.5-ml tube.
(c) Incubate the tube in a heat block at 65°C for 5 minutes, then immediately
transfer to ice for at least 1 minute or longer.
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(d) Load the sample on a 1% agarose TAE gel alongside GeneRuler 1 kb Plus
DNA ladder.
(e) Run the gel at 85 V for 45 minutes, then image using a UV gel imaging
system.
Note: Keep the remaining nascent RNA on ice while the gel is running before
proceeding to the next step. Optionally, stop here by storing the nascent RNA







Figure 2.3: Agarose gel showing intact chromatin-associated RNA.
A high-quality, intact sample should appear as a smear of different sizes of RNA,
and most should be larger than approximately 100 nt. Some abundant species may
cause distinct bands in the nascent RNA smear, and this is OK (Note: lanes show
two different unrelated samples).
PolyA + RNA Depletion
Prepare Magnetic Beads
23. Vortex the magnetic beads from the DynaBeads mRNA Direct Micro Purifi-
cation kit briefly to resuspend.
24. You will need to prepare 50 µl of beads for each sample. Because the deple-
tion will be performed in triplicate, prepare 3 volumes of beads plus 10% for
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pipetting error. Aliquot beads into a new 1.5-ml tube.
Note: E.g. For one sample, aliquot 50 µl x 3 x 10% = 165 µl beads.
25. Place the tube on a magnetic rack and allow the supernatant to clear (approx-
imately 1 minute).
26. Aspirate the supernatant with a P200 tip and discard. Remove the tube from
the magnetic rack.
27. Add 1 volume of lysis/binding buffer (from the DynaBeads mRNA Direct
Micro Purification kit) to the tube.
Note: E.g. for 165 µl beads, add 165 µl buffer.
28. Vortex briefly to mix, then centrifuge briefly (approximately 10 seconds) to
collect any drops from the lid.
29. Divide the beads equally into 3 1.5-ml tubes. (50 µl in each tube) and set aside.
PolyA+ Depletion
30. Adjust the volume of the input chromatin-associated RNA from step 21 to 300
µl with nuclease-free water.
31. Incubate RNA sample 2 min at 70°C.
32. Add an equal volume (300 µl) of lysis binding buffer (from the DynaBeads
mRNA Direct Micro Purification kit) to the RNA. Vortex briefly to mix, then
centrifuge briefly to collect any drops in the lid.
33. Pipette the RNA/buffer mixture prepared in step 32 on top of one of the 50 µl
aliquots of prepared magnetic beads. Pipette up and down ten times to mix.
34. Incubate the tube 5 min at room temperature.
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35. Place the tube on a magnetic rack and allow the supernatant to clear, approx-
imately 1 minute.
36. Carefully aspirate the supernatant and transfer to a clean 1.5-ml tube.
Note: This is the polyA-depleted fraction.
37. Incubate the polyA-depleted fraction 2 min at 70°C.
38. Repeat steps 33-37 two more times (for a total of three rounds of incubation,
with fresh beads each time), omitting the final 70°C incubation on the last
round.
Note: This is why 3 volumes of beads were required on Step 24.
39. Clean up the polyA-depleted RNA sample using the Clean and Concentrator-
5 kit, eluting in 30 µl nuclease-free water.
Note: Alternatively, ethanol precipitation can be used to clean up and concentrate
RNA.
40. Measure the concentration of polyA-depleted RNA by Nanodrop.
Note: Users should expect a concentration of 350-500 ng/µl with a 260/280 value
around 2.0, and a 260/230 value around 2.1. Note that a minimum of 10 µg of polyA+
depleted RNA is recommended before continuing to ribsomal RNA depletion.
Ribosomal RNA Depletion
Use RiboMinus™ Eukaryote Kit v2 on PolyA-depleted RNA
41. Add the components from the RiboMinus™ Eukaryote Kit in Table 2.2 to a
1.5-ml tube, in the order listed.
Note: The maximum input for the RiboMinus™ kit is 5 µg of RNA. You should
have more than this, so you will have to split the sample and do the rRNA depletion
in multiple aliquots, then combine all samples at step 60.
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Table 2.2: Ribominus™ probe hybridization reaction components.
Reagent Amount
2X hybridization buffer 50 µl
RiboMinus™ Eukaryote Probe Mix v2 4 µl
PolyA+ depleted RNA up to 5 µg
Nuclease-free water up to 100 µl
42. Mix by briefly vortexing at low speed, then centrifuge briefly to collect drops
from the lid.
43. Incubate 10 min in a heat block at 70°C to denature RNA.
44. Immediately transfer the tube to a second heat block at 37°C and allow the
sample to cool over a period of 20 minutes. Continue to the next step while
the sample is cooling.
Prepare RiboMinus™ Magnetic Beads
45. Resuspend the RiboMinus™ Magnetic Beads (from the RiboMinus™ Eukary-
ote Kit) by vortexing the bottle briefly.
Note: Be careful not to confuse the magnetic beads from the RiboMinus™ Eukary-
ote Kit with the previous magnetic beads from the DynaBeads mRNA Direct Micro
Purification Kit (step 23).
46. For each 5 µg RNA sample, prepare 200 µl of 1X hybridization buffer in a
new labelled tube by diluting 2X hybridization buffer (from the RiboMinus™
Eukaryote Kit) with an equal volume of nuclease-free water.
47. For each 5 µg RNA sample, pipette 500 µl of magnetic beads into a new 1.5-ml
tube. Place each tube on a magnetic rack to allow the supernatant to clear.
48. Gently aspirate and discard the supernatant.
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49. Remove the tubes from the magnetic rack and wash the beads with 500 µl
nuclease-free water by pipetting it down the side of the tube where the beads
are collected.
50. Place each tube on a magnetic rack to allow the supernatant to clear. Gently
aspirate and discard the supernatant.
51. Repeat washing (steps 49-50) one more time (for a total of 2 times).
52. Resuspend the beads in 200 µl of prepared 1X hybridization buffer from step
46.
53. Incubate the tube with beads in a heat block at 37°C for at least 5 minutes, or
until the 20 minute incubation of the RNA/probe mix at 37°C is complete.
Capture and Remove rRNA/Probe Complexes
54. Briefly centrifuge the RNA/probe mix to collect the mixture at the bottom of
the tube.
55. Add the RNA/probe mix to the prepared RiboMinus™ Magnetic beads from
step 53. Mix by pipetting up and down ten times.
56. Incubate the tube in a heat block at 37°C for 5 min. Centrifuge briefly to collect
drops.
57. Place the tube on a magnetic rack and allow the supernatant to clear, approx-
imately 1 minute.
58. Transfer the supernatant (approximately 300 µl) to a new 1.5-ml tube.
Note: This is the rRNA-depleted fraction.
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59. Concentrate and clean up rRNA-depleted RNA by ethanol precipitation:
Note: Alternatively, use the magnetic bead clean up kit that comes with some ver-
sions of the RiboMinus™ Eukaryote Kit. In my experience, it can be difficult for
inexperienced users to work with very small volumes on magnetic beads, therefore, I
recommend ethanol precipitation.
(a) Add 1 µl glycogen (20 µg/µl), 0.1 volumes 3 M sodium acetate, and 2.5
volumes of ice-cold 100% ethanol to the tube with the RNA.
Note: Adding glycogen is optional, but it helps to generate a visible pellet.
(b) Mix well by pipetting up and down, then incubate at least 30 minutes at
-80°C.
Note: Incubate up to overnight at -80°C.
(c) Centrifuge 15 min at 14,000 rpm, 4°C.
(d) Carefully aspirate and discard the supernatant without disturbing the
pellet.
(e) Add 500 µl of ice-cold 70% ethanol to rinse the pellet.
(f) Centrifuge 5 min at 14,000 rpm, 4°C.
(g) Carefully aspirate and discard the supernatant without disturbing the
pellet.
(h) Repeat the wash with ice-cold 70% ethanol one more time (for a total of
2 washes).
Note: When aspirating the supernatant the second time, be sure to remove as
much ethanol as possible. It can help to use a P1000 pipette tip to remove most
of the ethanol. Then, centrifuge the tube briefly and use a P10 pipette tip to
remove the final few drops.
(i) Air dry the pellet with the lid open for 5 min at room temperature.
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60. Resuspend the pellet in 7 µl nuclease-free water.
Note: Combine multiple samples (divided in step 41) into one 1.5-ml tube at this
point. Start by resuspending the first pellet in 7 µl nuclease-free water, then use this
same 7 µl to resuspend further pellets.
61. Measure the concentration of RNA by Nanodrop.
Note: Users should expect a concentration of 110-210 ng/µl. Note that it is very
important to have at least 600 ng of nascent RNA in a volume of at most 5.5 µl for
the next step, or a minimum concentration of 110 ng/µl before proceeding. For more
details, see the Critical Parameters section.
Adapter Ligation
62. Add 600 ng of nascent RNA (in a volume of up to 5.5 µl) and 50 ρmol of DNA
adapter (0.5 µl of a 100 ρmol/µl dilution) to a 0.2-ml PCR strip tube. If neces-
sary, adjust the volume to 6 µl with nuclease-free water. Mix by gently flicking
the tube, then centrifuge briefly to collect drops.
Note: Note that the DNA adapter sequence (/5rApp/NNNNNCTGTAGGCACCATC
AAT/3ddC/) includes an activated adenylate group at the 5′ end (5rApp), a sequence
of 5 random nucleotides (NNNNN), and a dideoxynucleotide at the 3′ end (3ddC).
All three of these custom features must be included when ordering this oligo from a
vendor. The adapter should be diluted to 100 ρmol/µl and aliquoted upon arrival,
then stored at -20°C.
63. Incubate 10 min in a thermal cycler at 65°C, then transfer to ice for at least 1
minute.
64. During the incubation of step 63, prepare a master mix (enough for all sam-
ples) for the adapter ligation reaction from the components of the T4 RNA
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ligase kit, as listed in Table 2.3. Add the master mix components to a 1.5-ml
tube.
Table 2.3: Adapter ligation reaction components.
Reagent Amount
10X ligase buffer 2 µl
50% PEG 8000 10 µl
RNase OUT 1 µl
RNA ligase 2 (truncated K227Q) 1 µl
65. Mix very well by pipetting up and down.
Note: PEG is very viscous, and the success of the adapter ligation reaction can depend
on how well it is mixed at this stage. Avoid incorporating bubbles by keeping the
pipette tip submerged.
66. Add 14 µl of adapter ligation master mix to the 6 µl annealed RNA sample
(from Step 63) and mix very well again by pipetting up and down. Centrifuge
briefly to collect drops.
67. Incubate in a thermal cycler for 12 hours at 16°C, then hold at 4°C.
68. Adjust the volume of the adapter ligation reaction to 100 µl with nuclease-free
water.
69. Clean up and concentrate adapter-ligated RNAusing the Clean and Concentrator-
5 kit, eluting in 10 µl nuclease-free water.
Note: Alternatively, ethanol precipitate RNA as described above.
2.1.5 Basic Protocol 3: cDNA Amplicon Preparation
This library preparation protocol generates a double-stranded cDNAmolecule from
each nascent RNA that retains the unique nascent RNA 3′ end adapter sequence.
First, a template-switching reverse transcriptase generates both the first and second
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strand of cDNA in a single step (Zhu et al., 2001), which allows templates with het-
erogeneous 5′ ends to be incorporated into the library. Importantly, RNAs with a
5′ end that is TMG-capped are incorporated more efficiently than uncapped RNAs
(Wulf et al., 2019), which helps enrich for full length RNAs in the library. First, a test
is performed to determine the optimal number of PCR cycles to use when amplify-
ing the cDNA. This is to avoid over-amplifying the sample and introducing a size
bias in the final library. Then, a final PCR reaction is performed using the optimal
number of PCR cycles, and the sample is cleaned up before continuing to generate
a long read sequencing library. This protocol is compatible with barcoding.
Materials
Reagents and Chemicals
• Adapter-ligated nascent RNA (from Basic Protocol 2 step 69)
• Custom RT primer, 10µM (AAGCAGTGGTATCAACGCAGAGTACCACATA
TCAGAGTGCGGATTGATGGTGCCTACAG; where the region in bold is a
16-nt barcode, see Critical Parameters section for more details)
• TE buffer (10 mM Tris·HCl, 0.1 mM EDTA, pH 8.0)
• 6X Orange DNA loading dye (Thermo Fischer Scientific, cat. no. R0631)
• SMARTer PCR cDNA Synthesis Kit (Takara/Clontech, cat. no. 634925)
• Advantage 2 PCR kit (Takara/Clontech, cat. no. 639137)
• TAE buffer (40 mM Tris·HCl, 20 mM acetic acid, 1 mM EDTA pH 8.0)
• Agarose (Sigma, cat. no. A9539)
• Lonza Gelstar (Thermo Fischer Scientific, cat. no. 50535)
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• GeneRuler 1 kb Plus DNA ladder (Thermo Fischer Scientific, cat. no. SM1331)
• AMPure XP beads (Beckman Coulter, cat. no. A63880)
• 70% ethanol, room temperature
• 10 mM Tris·HCl pH 8.5
Equipment
• 0.2-ml PCR strip tube (Dot Scientific, cat. no. 415-8PCR)
• Thermal cycler




• 1.5-ml tube magnetic rack
• Nanodrop
• UV gel imaging system
Protocol Steps
Reverse Transcription
1. For each sample, add 3.5 µl adapter ligated RNA (from step Basic Protocol 2
step 69; approximately 210 ng) and 1 µl custom RT primer (10 µM) to a new
0.2-ml tube labeled “+RT”. Add the same to a new 0.2-ml tube labeled “-RT”.
Mix by gently flicking the tubes, then centrifuge briefly to collect drops.
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Note: If multiple samples are to be barcoded, different RT primers with unique bar-
code sequences should be used for each sample here.
2. Incubate tubes in a thermal cycler for 3 min at 72°C, then 2 min at 42°C, then
hold at 4°C until the next step is prepared.
3. During the incubation of step 2, prepare two master mixes for the reverse
transcription reaction from the components of the SMARTer PCR cDNA Syn-
thesis Kit, as listed in Table 2.4. Add master mix components to a 1.5-ml tube
in the order listed below. Prepare enough master mix for all samples. Make
one master mix including the SMARTScribe RT enzyme and one mix without
the enzyme, using nuclease-free water in its place.
Note: For example, if you are preparing 4 samples, prepare a 5X master mix with RT
enzyme, and a 5X master mix without RT enzyme.
Table 2.4: Reverse transcription reaction components.
Reagent Amount
5X First Strand buffer 2 µl
100 mM DTT 0.25 µl
10 mM dNTP mix 1 µl
12 µM SMARTer IIA Oligo (stored at -80°C) 1 µl
RNase Inhibitor 0.25 µl
SMARTScribe Reverse Transcriptase (100U) 1 µl
4. Add 5.5 µl of master mix with SMARTScribe RT enzyme to the 0.2-ml tubes
from step 1 labeled “+RT”, and add 5.5µl of master mix without SMARTScribe
RT enzyme to the 0.2-ml tubes labeled “-RT”. Mix by gently flicking the tubes,
then centrifuge briefly to collect drops.
5. Incubate in thermal cycler for 90 min at 42°C, then terminate the reaction by
incubating 10 min at 70°C, and then hold at 4°C.
6. Dilute each reaction 1:10 with 90 µl TE buffer.
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7. Divide each reaction into 10-15 µl aliquots in labeled 0.2-ml PCR strip tubes
and freeze immediately at -20°C if stopping here. Store at -20°C for up to three
months. Otherwise, keep the tubes on ice and proceed immediately to PCR
optimization.
PCR Cycle Number Optimization
8. Assemble a master mix for PCR reactions from the components of the Advan-
tage 2 PCR kit, as listed in Table 2.5. For each cDNA sample (both +RT and
-RT), assemble enough master mix for one PCR reaction.
Table 2.5: PCR cycle number optimization reaction components.
Reagent Amount
cDNA 5 µl
10X Advantage 2 buffer 5 µl
50X dNTP mix (10 µM) 1 µl
Primer IIA (12 µM) 1 µl
50X Advantage 2 Polymerase 1 µl
Nuclease-free water 37 µl
9. Add 5 µl of each cDNA sample from step 7 to a new 0.2-ml PCR strip tube,
then add 45 µl of the master mix on top. Mix by gently flicking the tube and
then centrifuge briefly to collect drops.
10. Place the PCR strip in a thermal cycler with the cycle program indicated in
Table 2.6. After the initial 8 rounds of amplification, hold the thermal cycler at
4°C, open the thermal cycler lid, and remove a 5 µl aliquot from each reaction.
Close the lid and continue cycling for an additional 2 rounds (for a total of 10
rounds), then take out another 5 µl aliquot. Repeat until the sample has gone
through a total of 18 cycles of amplification and you have a 5 µl aliquot after
every 2 cycles. Keep the aliquots at 4°C until the final round is completed.
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Note: The cycle numbers that are tested may need to be adjusted, but I recommend
8-18 cycles as a starting point.
Table 2.6: PCR cycle number optimization thermal cycler program.
Temperature (°C) Time Cycles
95 1 min 1
95 15 s
8, 10, 12, 14, 16,1865 30 s
68 3 min
4 hold –
11. Add 1 µl 6X gel loading dye to each aliquot and run all aliquots on a 1% TAE
agarose gel at 85 V for 45 min alongside 0.2 µl of GeneRuler 1 kb plus ladder.
Load reactions from corresponding +RT and -RT cDNA aliquots at each cycle
number for comparison (Figure 2.4). Each sample will require 12 lanes plus a
ladder. Run the gel at 85 V for 45 minutes, then image using a UV gel imaging
system.
12. Select the cycle number to be used for the final PCR amplification. For all
samples, the -RT reactions should be empty, and the +RT reactions should
show a gradually increasing smear of cDNA with increasing cycle number.
The optimal cycle number is one where the cDNA is visible, but before it gets
too dark and overloaded.
Note: For the example shown in Figure 2.4, a cycle number of 14 should be chosen.
Final PCR Amplification
13. For each sample, prepare enough master mix for 8 50 µl PCR reactions using
the Advantage 2 PCR kit, according to Table 2.5.
14. Add 5 µl of +RT cDNA to 8 0.2-ml PCR strip tubes, then add 45 µl of master
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Figure 2.4: Agarose gel showing aliquots from PCR cycle number optimization.
On the left, “+RT” samples contain the RT enzyme in the reverse transcription re-
action, and on the right, “-RT” control samples that do not contain the RT enzyme.
Numbers at the top of the gel indicate the number of PCR amplification cycles.
Numbers at the left of the gel indicates size of the DNA ladder in basepairs. The
red arrow indicates the optimal cycle number in this example, based on the inten-
sity of the cDNA smear.
collect drops.
15. Place the PCR strip in a thermal cycler with the cycle program indicated in
Table 2.7.
Table 2.7: Final LRS library PCR thermal cycler program.
Temperature (°C) Time Cycles
95 1 min 1
95 15 s
Optimized cycle number65 30 s
68 3 min
68 5 min 1
4 hold –
16. Combine the 8 PCR reactions for each sample (400 µl total) into a new 1.5-ml
tube, and remove a 5 µl aliquot from each sample to run on a gel.
17. Run the 5 µl aliquot from each sample on a 1% TAE agarose gel at 85 V for 45
min to confirm that PCR amplification worked, and that the smear appears
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the same as in the cycle optimization test (from step 12).
AMPure Bead PCR Cleanup
18. Mix AMPure beads by gently vortexing the bottle.
19. Add 1X volume of AMPure magnetic beads to each pooled PCR sample (400
µl).
20. Mix the beads/DNA solution thoroughly by vortexing. Centrifuge briefly to
collect drops.
21. Allow the DNA to bind to the beads by shaking in a Thermomixer at 1,400
rpm for 10 minutes at room temperature. Centrifuge the tube briefly to collect
drops.
22. Place the tube in a magnetic rack and allow the supernatant to clear (at least
1 minute).
Note: In my experience, these beads take slightly longer than usual to clear. If the
supernatant is still cloudy after 1 minute, wait longer.
23. With the tube still on the magnetic rack, carefully aspirate and discard the
cleared supernatant. Make sure you avoid disturbing the bead pellet.
24. Wash the beads with 500 µl of room temperature 70% ethanol by pipetting it
down the side of the tube where the beads are.
25. With the tube still on the magnetic rack, carefully aspirate and discard the
supernatant. Repeat once, for a total of 2 ethanol washes.
26. Centrifuge the tube briefly to collect beads and residual ethanol in the bottom
of the tube, then place the tube back in the magnetic rack and carefully aspi-
rate any residual ethanol with a P10 pipette tip.
52
Note: It is important to remove as much ethanol as possible without disturbing the
pellet.
27. Open the tube lid and air dry for 1 minute at room temperature.
28. Add 40 µl of 10 mM Tris·HCl pH 8.5 to the beads to elute the DNA.
29. Shake the tube in a Thermomixer for 10 minutes at 1,400 rpm at room tem-
perature. Centrifuge the tube briefly to collect drops.
30. Place the tube in the magnetic rack and allow the supernatant to clear (at least
1 minute).
31. Carefully aspirate the supernatant and transfer it to a new 1.5-ml tube.
Note: This is the final eluted DNA sample. Be very careful not to carry over any ex-
cess magnetic beads during this step. If you are unsure, place the eluted supernatant
back on the magnetic rack and repeat.
32. Determine the concentration of the final DNA sample by Nanodrop.
Note: Users should expect a final concentration of 50 – 200 ng/µl, although this will
vary depending on the intensity of the cDNA smear that was chosen for the optimal
cycle number.
33. If preparing multiple barcoded samples, pool all barcoded samples together
in equal concentrations (i.e. put equal ng amount of each in the same tube).
The final sample volume will vary depending on the library preparation ser-
vice you choose, but 50 µl is an approximate volume to aim for.
Note: Library preparation should now be completed following manufacturer’s in-
structions for amplicon sequencing on the long-read sequencing platform of your
choice.
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2.1.6 Reagents and Solutions
All buffers should be prepared from stock solutions up to 1 week before use and
stored at 4°C, excludingα-amanitin, SUPERase.IN, and cOmplete protease inhibitor
mix, which should be added immediately before use. All buffers should be chilled
on ice before use.
Cell lysis buffer
10 mM Tris·HCl pH 7.5
0.05% NP-40 (Sigma, cat. no. 9016-45-9)
150 mM NaCl
25 µM α-amanitin (Sigma, cat. no. A2263)
40 U/ml SUPERase.IN (Thermo Fischer Scientific, cat. no. AM2694)
1X cOmplete protease inhibitor mix (Sigma, cat. no. 11697498001)
Nuclear Lysis Buffer
20 mM HEPES pH 7.5





1% NP-40 (Sigma, cat. no. 9016-45-9)
25 µM α-amanitin (Sigma, cat. no. A2263)
40 U/ml SUPERase.IN (Thermo Fischer Scientific, cat. no. AM2694)
1x cOmplete protease inhibitor mix (Sigma, cat. no. 11697498001)
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Nuclear Resuspesion Buffer
20 mM Tris·HCl pH 8.0
75 mM NaCl
0.5 mM disodium EDTA
0.85 mM dithiothreitol (DTT)
50% (v/v) glycerol
25 µM α-amanitin (Sigma, cat. no. A2263)
40 U/ml SUPERase.IN (Thermo Fischer Scientific, cat. no. AM2694)
1x cOmplete protease inhibitor mix (Sigma, cat. no. 11697498001)
Sucrose Buffer
Cell lysis buffer with 24% (w/v) sucrose
Note: Add sucrose crystals to prepared cell lysis buffer and mix on a rotary spinner at room
temperature until sucrose is dissolved (15 – 30 min).
2.1.7 Troubleshooting
Fractionation Issues
All fractionation issues should be diagnosed by Western blot of the cytoplasmic,
nucleoplasmic, and chromatin fractions. If nucleoplasm or chromatin markers are
present in the cytoplasm, the initial centrifugation speed may have been so high
that nuclei lysed in the sucrose buffer purification step. Try decreasing centrifu-
gation speed. Additionally, nuclei can be observed under a microscope after this
step to ensure they are intact (visibly round). You may also try to decrease the time
that cells are incubated with the cell lysis buffer. If the nuclei are difficult to resus-
pend after pelleting (sticky rather than loosely suspended after flicking the tube),
the nuclei may have been prematurely lysed as well. Conversely, if markers for the
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nucleoplasm or chromatin are significantly detected in the cytoplasm, the centrifu-
gation speed may not have been high enough to pellet the nuclei, and you may
thus wish to increase the centrifugation speed.
RNA Isolation Issues
If at any point during the RNA isolation you end up with less RNA than recom-
mended for the next step, you may either pool multiple samples together to gain
enough RNA, or freeze the RNA at -80°C for up to one month while you go back
and repeat the previous steps to obtain enough RNA. If the nascent RNA appears
degraded on the gel after RNA isolation (a high concentration of small RNAs, no
larger RNAs), it is possible that there was RNase contamination. Throw out this
RNA sample and repeat from the beginning. Make sure that you are using sterile
RNAse-free materials, work quickly while handling the RNA samples, don’t touch
any tips/tubes accidentally to other surfaces, and keep all tubes that contain RNA
on ice unless otherwise noted.
Adapter Ligation Issues
The adapter ligation reaction is usually greater than 90% efficient (Carrillo Oester-
reich et al., 2016), but the efficiency can drop if the reaction is not thoroughly mixed
before incubation. If you suspect the adapter ligation reaction is not working, for
example if the downstream PCR reactions do not yield a product and you have
ruled out other issues with RT or PCR (see next point), you can diagnose this prob-
lem by running a sample of nascent RNA with and without T4 RNA ligase included
in the ligation reaction on a 10% TBE-urea denaturing gel (Figure 2.5). In a suc-
cessful ligation, you should be able to see all the major bands in the nascent RNA
sample shift upward when the DNA adapter is present in the reaction.
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- ligaseladder + ligase
Figure 2.5: Denaturing agarose gel showing successful adapter ligation.
(-) ligase lane contains the adapter ligation reaction mix in the absence of T4 ligase,
and (+) ligase lane contains T4 ligase. Successful ligation results in a shift upwards
of all major RNA species, as indicated by the red arrows.
RT and PCR Issues
If no PCR product appears even after 18 cycles of amplification, the adapter liga-
tion reaction may not have worked efficiently. Repeat from this step, ensuring the
reaction is mixed well. If there is PCR product in the -RT control lanes as well as the
+RT lanes, there may be some DNA contamination in the sample. Repeat DNase
I treatment if this occurs. If some RNA sequences are very abundant in your cell
type, this may appear as a distinct band in the cDNA “smear” (Figure 2.4) – this is
OK. However, sometimes a high molecular weight smear appears (in the range of
5-20 kb), and this is generally non-specific amplification. A cycle number should
be chosen before this high molecular weight smear appears.
2.1.8 Expected Results
Sequencing a cDNA library from 60 million MEL cells on one PacBio Sequel flow
cell should yield up to 1 million reads, and typically 68% map uniquely to the
mouse genome. Polyadenylated reads can be bioinformatically filtered but should
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be minimal (typically around 1%). PCR duplicates can be identified by reads which
contain the same barcode in the DNA adapter sequence. However, at this sequenc-
ing depth, PCR duplicates are not frequently sequenced (typically less than 1%).
The resulting long reads generally have a median length of approximately 720 nu-
cleotides.
2.1.9 Time Considerations
The full protocol described here can be completed in 4 days. On day 1, actively
growing MEL cells can be harvested and fractionated, then a diagnostic Western
blot can be run. On day 2, nascent RNA can be isolated from the chromatin pellet
in Trizol, then polyA+ and rRNA depletion can be completed. Adapter ligation
should also be done at the end of this day, since it is the only step that requires
an overnight incubation. On day 3, the RT reaction and PCR cycle number opti-
mization can be done. On day 4, the final PCR amplification and clean up can be
performed. However, there are flexible stopping points mentioned in the protocol.
The most time-sensitive steps are on the first day – it is best to get the live cells
harvested and precipitate the chromatin as fast as possible.
2.2 Cell Lines, Cell Culture, and Cell Treatments
Murine Erythroleukemia cells (MEL; obtained from Shilpa Hattangadi, Yale School
of Medicine) were maintained at 37°C and 5% CO2 in DMEM + Glutamax medium
(GIBCO) containing 100 U/ml penicillin, 100 µg/ml streptomycin (GIBCO), and
10% fetal bovine serum (GIBCO). To induce erythroid differentiation, cells were
diluted to 50,000 cells/ml in 10 ml fresh culture medium and incubated as above
for 16 hours. dimethyl sulfoxide (DMSO) was then added directly to the culture
medium to a final concentration of 2% and incubated as above for 5 days. For Pla-
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dienolide B treatment, cells were diluted to 50,000 cells/ml in fresh culture medium,
then incubated as above for two days until reaching a density of approximately 5
million cells/ml. Pladienolide B (Santa Cruz) dissolved in DMSO was added di-
rectly to the culture medium at a final concentration of 1 µM. MEL-HBBWT and
MEL-HBB IVS-110(G>A) cell lines are described previously (Patsali et al., 2018), and
were maintained and differentiated as above.
2.3 qPCR
Total RNA was extracted from 10 million cells in TRIzol Reagent (ThermoFisher)
according to the manufacturer’s protocol after 0, 2, 4, or 6 days of treatment with
2% DMSO as described above. cDNA was generated with SuperScript III Reverse
Transcriptase (ThermoFisher) using random hexamer primers (ThermoFisher) ac-
cording to the manufacturer’s protocol. For primers used to amplify Hbb-b1 and
Gapdh, see Table 5.3. qPCR reactions were assembled using iQ SYBR Green Super-
mix (BioRad) and quantified on a Stratagene MX3000P qPCR machine. Expression
fold changes were calculated using the ∆∆Ct method.
2.4 Microscopy
Live cells were imaged in bright field on an Olympus CKX41 microscope.
2.5 RT-PCR After Pladienolide B Treatment
For total RNA samples, RNA was extracted from approximately 5 million cells
treated with Pladienolide B as described above and using TRIzol Reagent (Ther-
moFisher) according to the manufacturer’s protocol. For nascent RNA samples,
RNA was extracted from the chromatin pellet after subcellular fraction as described
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above, except with the addition or not of Pladienolide B to all subcellular fraction-
ation buffers at a final concentration of 1 µM. PolyA+ RNA was further depleted
from this sample as described above. cDNA was generated from all RNA samples
with SSIII RT (ThermoFisher) using random hexamer primers (ThermoFisher) ac-
cording to the manufacturer’s protocol. PCR was performed using Phusion High-
Fidelity DNA Polymerase (NEB) according to the manufacturer’s protocol. For the
list of intron-flanking primers used in these experiments, see Table 5.3.
2.6 HBB Targeted Nascent RNA Library Preparation
Nascent RNA was isolated as described above from cells treated with 2% DMSO
for 5 days, except that polyA+ and ribosomal RNA depletion steps were omitted.
A DNA adapter was ligated to 3′ ends as above, and custom RT primers were used
to add barcodes during reverse transcription with SSIII reverse transcriptase (Ther-
moFisher; Table 5.3). cDNA was amplified by 26 cycles of PCR using the Advan-
tage 2 PCR Kit (Clontech), but with custom gene-specific forward primers that were
complementary to either a unique region in the 5′UTR of the human HBB gene or
the endogenous mouse Hbb-b1 gene in combination with the SMARTer IIA primer
(Clontech). PCR amplicons were cleaned up with a 2X volume of AMPure beads
(Agencourt), and PacBio library preparation was performed at the Icahn School of
Medicine at Mt. Sinai Genomics Core Facility using the SMRTbell Template Prep
Kit 1.0 (Pacific Biosciences). The library was sequenced on one Sequel 1 flowcell.
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2.7 Long-read Sequencing Data Analysis
2.7.1 Genome-wide nascent RNA sequencing data preprocessing
Combined consensus sequence (CCS) reads were generated in FASTQ format, and
Porechop was used to separate chimeric reads and trim external adapters with the
SMRTer IIA sequences AAGCAGTGGTATCAACGCAGAGTAC and GTACTCT-
GCGTTGATACCACTGCTT with settings --extra_end_trim 0 --extra_middle_
trim_good_side 0 --extra_middle_trim_bad_side 0 --min_split_read_size
100. Cutadapt was used to remove the unique 3′ end adapter on all reads in two
rounds of filtering. First, any reads with the adapter at the 3′ end were trimmed
with settings -a CTGTAGGCACCATCAAT -e 0.1 -m 15 --untrimmed-output=
untrimmed.fastq, and any reads which did not contain the full adapter were re-
tained and their reverse complement was generated. Then, a second round of
filtering with cutadapt using the settings -a CTGTAGGCACCATCAAT -e 0.1 -m 15
--discard-untrimmed was used to remove adapters from the reverse comple-
ment reads, and reads without the 3′ adapter were discarded. This ensures that
each read contains a successfully ligated 3′ adapter which marks Pol II position,
and since sequencing occurs in both forward and reverse orientations randomly,
it places all reads in the correct 5′ to 3′ orientation. Reads from the two adapter
trimming steps were combined into a single file, then Prinseq-lite was used to re-
move PCR duplicates with settings -derep 1. Prinseq-lite was used again to trim
6 non-templated nucleotides added at the 5′ end by the strand-switching reverse
transcriptase and the 5 nt of the 3′ end adapter UMI with settings -trim_left 6
-trim_right 5. Reads were then mapped to the mm10 genome using minimap2
with settings -ax splice -uf -C5 --secondary=no, and the resulting SAM files
were converted to BAM and BED files for downstream analysis using samtools and
bedtools. Reads overlapping the 7SK genomic region (chr9:78175302-78175633
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in the mm10 genome) were filtered using samtools before all downstream anal-
yses. Non-unique reads (reads with the same read name appearing more than
once in SAM files) were removed. All data generated using Nanopore sequenc-
ing from (Drexler et al., 2020) (GEO accession ID: GSE123191) were downloaded
in FASTQ format and mapped to either the hg38 or dm6 genome using minimap2
with settings -ax splice -ut -k14, then converted to SAM, BAM, and BED for-
mats as above, and non-unique reads were also removed. All data were visualized
in and exported from IGV to generate genome browser figures. In all analysis ex-
cept where noted, LRS data are represented as two biological and two technical
replicates combined.
2.7.2 HBB targeted nascent RNA sequencing data preprocessing
Porechop was used on raw FASTQ reads to remove external adapters and separate
chimeric reads with the common forward sequence and the SMRTer IIA reverse se-
quence GACGTGTGCTCTTCCGATCT and GTACTCTGCGTTGATACCACTGCTT
(as well as the reverse complement sequences) with settings --extra_end_trim 0
--extra_middle_trim_good_side 0 --extra_middle_trim_bad_side 0 --min_
split_read_size 100 --middle_threshold 75. Reads were filtered and trimmed
if they contained the 3′ end adapter as described above using the 3′ end adapter
sequence plus the barcode sequence (Table 5.3). Prinseq was used to demultiplex
and trim reads as above, then cleaned FASTQ files were mapped to a custom an-
notation of the integrated HBB locus, which is based on the GLOBE vector (Miccio
et al., 2008).
62
2.7.3 PolyA+ Read Filtering
Genome-wide nascent RNA sequencing data
Mapped reads in SAM format were filtered to remove reads that contained a polyA
tail using a custom script (available at https://www.github.com/NeugebauerLab/
MEL_LRS). Briefly, mapped reads that had soft-clipped bases at the 3′ end were dis-
carded if the soft-clipped region of the read contained 4 or more A’s and the fraction
of A’s was greater than 0.9. Similarly, reads with soft-clipped bases at the 5′ end (re-
sulting from minus strand reads) containing at least 4 T’s and having a fraction of
T’s greater than 0.9 were discarded.
HBB targeted nascent RNA sequencing data
Additional parameters were added to the above criteria for removing polyA+ reads
from targeted data mapped to the HBB locus based on empirical observation. Since
the HBB locus is integrated randomly in the MEL genome, long uncleaved tran-
scripts that have coverage past the annotated HBB locus read into random genomic
regions and cause long stretches of mismatched soft-clipped bases. A custom script
was used to filter polyA-containing reads but retain uncleaved transcripts (avail-
able on Github). Briefly, reads were discarded if: they contained a fraction of A’s
or T’s greater than 0.7 in the soft-clipped region that starts past the end of the HBB
locus annotation; they contained a fraction of A’s or T’s greater than 0.7 and 4 or
more A’s or T’s in the soft-clipped region starting within 50 nt of the annotated PAS;
they contained a stretch of soft-clipped reads greater than 20 nt that starts within
the annotated HBB gene. Uncleaved reads with long stretches of soft-clipped bases
that passed this filtering were then recoded to contain a match in the CIGAR string
downstream of the PAS in order to include these regions of the long-reads in cov-
erage calculations.
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2.7.4 Splicing Status Classification and Co-transcriptional Splic-
ing Efficiency (CoSE) Calculation
The annotation of introns contained in active transcripts (described below for PRO-
seq), was first filtered for unique intron start and end coordinates. Additionally, an
upstream intron in Hbb-b1 that was clearly not used in the LRS reads was removed
(ENSMUST00000153218.1_intron_1_0_chr7_103827887_r). The resulting introns
were extended by 1 nt on either end and were overlapped with bed files of long-
reads using bedtools intersect in order to get regions of long-reads that spanned
entire introns. Spliced junction coordinates in intron-overlapping long-reads were
compared to the coordinates of each intron they overlapped to determine if the
overlapped intron was spliced in the read. If the junction was not present in the
read, a 10 nt window was included in the search for the junction to allow for slight
mismatches in alignments. If the junction was not found, the intron was classified
as unspliced. Next, reads which did not span the entire intron, but reached at least
35 nt upstream of a 3′SS and were unspliced were counted toward the unspliced
count for an intron. To classify splicing status of each read, the number of spliced
introns was compared to the total number of introns that was overlapped. To cal-
culate co-transcriptional splicing efficiency (CoSE), the splicing status classification
of each intron was recorded as above, and the number of spliced introns and un-
spliced introns was summed per intron. Introns with identical 5′SS or 3′SS were
filtered to keep only the intron with the most total reads. Introns with no spliced
reads (no evidence of usage in MEL cells), introns that were longer than 10 kb, and
introns covered by fewer than 10 reads were removed. For the remaining introns,
CoSE was calculated by dividing the number of spliced reads by the total number
of reads.
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2.7.5 Distance From Splice Junction to 3′ End Calculation
Splicing intermediates (defined below), were filtered out from the long-read data
in this analysis, since their 3′ ends do not represent the position of Pol II, but rather
an upstream exon between step I and step II of splicing. For all remaining reads,
data were filtered for reads that contained at least 1 splice junction, and then the
last “block size”, which represents the distance from the most distal splice junction
to the 3′ end of the read, was calculated. Coordinates of the last spliced intron were
also recorded, and each intron was matched to a transcript and categorized by gene
biotype using mygene in python. Introns were matched to their corresponding
transcript expression level using PRO-seq TSS counts as described below. To deter-
mine if certain genes exhibited a longer or shorter distances from 3′ ends to splice
junctions, the distance was split into three equal size categories and transcript IDs
from each category were entered into the online PANTHER classification system:
no significant enrichment was obtained.
2.7.6 Splicing Intermediates Analysis
Long-reads were categorized as being splicing intermediates if the 3′ end of the
read aligned exactly at the -1 position of an intron (last nucleotide of an exon). In-
trons considered in this analysis were the same set of introns considered for CoSE
as described above. The number of intermediates aligned upstream of each intron
was counted using bedtools intersect. The Normalized Intermediate Count (NIC)
was calculated for each intron which was covered by at least 10 reads (as above)
by dividing the number of splicing intermediate reads by the sum of splicing inter-
mediate reads and spliced reads. The sequence of the 23 nt region surrounding the
intron 3′SS (-20:+3) and the 9 nt region surrounding the 5′SS (-3:+6) were extracted
using bedtools getfasta, and these sequences were used to calculate 5′ and 3′ splice
site scores using MaxEntScan (Yeo and Burge, 2004).
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2.7.7 Long-Read Coverage
Transcript coordinates associated with active transcription start sites (as described
below) were obtained from the UCSC Table Browser. Transcripts were then grouped
by the parent Gene ID, and the largest range of start and end coordinates from the
grouped transcripts was kept. Library depth was then calculated using bedtools
coverage across this file of collapsed active gene coordinates. Metagene plots of 5′
end, 3′ end, and entire read coverage across the same gene coordinates were gener-
ated using deepTools. Briefly, coverage was calculated and normalized by RPKM
using the bamCoverage function, then coverage was scaled over all genes using the
computeMatrix scale-regions function, and plots were generated using the plotPro-
file function. For coverage downstream of the PAS, long-reads were separated by
splicing status (see above), then coverage was calculated using bedtools within a
window around PASs that corresponded to active TSSs or specifically to a window
around the HBB PAS. Coverage at all positions was normalized to the coverage at
the position 100 nt upstream of the PAS. For coverage of splicing intermediates,
bedtools coverage was used to calculate coverage of 5′ ends and 3′ ends across a
50-nt window around 5′SS and 3′SS of introns contained in active transcripts.
2.7.8 Uncleaved Transcripts Analysis
Bedtools intersect was used to identify long-reads with 5′ ends originating in a gene
body of active transcripts (as described below). Reads were then categorized as be-
ing uncleaved transcripts if their 3′ ends were greater than 50 nt downstream of
the PAS of the gene which the 5′ end overlapped with. In the case where a read
5′ end intersected multiple overlapping transcripts, it was only assigned as an un-
cleaved read if the 3′ end was downstream of all transcript PASs. Splicing status
classification of uncleaved transcripts was carried out as described above.
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2.7.9 HBB- IVS110(G>A) Splicing and 3′ End Cleavage Analysis
For long-reads derived from HBB-IVS110(G>A) cells, only reads that were spliced at
intron 1 using the cryptic splice site were analyzed, and the rare reads with a splice
junction using the canonical splice site were discarded. Splicing status classifica-
tion, counting of splicing intermediates, and calculating coverage downstream of
the PAS were performed as described above but with the custom HBB annotation
coordinates.
2.8 PRO-seq Library Preparation and Data Analysis
2.8.1 Cell Permeabilization
All buffers were cooled on ice, all steps were performed on ice, and all samples
were spun at 300 xg at 4°C unless otherwise noted. MEL cell differentiation was
induced as previously described. Uninduced and induced cells were washed with
PBS and resuspended in 1 ml Buffer W (10 mM Tris·HCl pH 8.0, 10 mM KCl, 250
mM sucrose, 5 mM MgCl2, 0.5 mM DTT, 10% glycerol), then strained through a
40 µm nylon mesh filter. 9X volume of Buffer P (Buffer W + 0.1% IGEPAL CA-
630) was immediately added to each sample, cells were nutated for 2 minutes at
room temperature, then spun for 4 minutes. Cells were washed in Buffer F (50 mM
Tris·HCl pH 8.3, 40% glycerol, 5 mM MgCl2, 0.5 mM DTT, 1 µl/ml SUPERase.In
[ThermoFisher]), then resuspended in Buffer F at a final volume of 1 x 106 perme-




One million permeabilized uninduced and induced MEL cells were spiked with
5% permeabilized Drosophila S2 cells for data normalization and used as input
for PRO-seq. Three biological replicates were generated per treatment condition.
Nascent RNA was labeled through a biotin-NTP run-on: permeabilized cells was
added to an equal volume of a 2X run-on reaction mix (10 mM Tris-HCl pH 8.0, 300
mM KCl, 1% Sarkosyl, 5 mM MgCl2, 1 mM DTT, 200 µM biotin-11-A/C/G/UTP
(Perkin-Elmer), 0.8 U/µl SUPERase.In [ThermoFisher]), and incubated at 30°C for
5 min. RNA was isolated using the Total RNA Purification Kit (Norgen Biotek
Corp). Fragmentation of isolated RNA was performed by base hydrolysis with
0.25 N NaOH for 9 minutes on ice, followed by neutralization with 1X volume of 1
M Tris·HCl pH 6.8. To select for nascent RNAs, 48 µl of washed Streptavidin M-280
magnetic beads (ThermoFisher) in binding buffer (300 mM NaCl, 10 mM Tris·HCl
pH 7.4, 0.1% Triton X-100) was added to the fragmented RNA, and samples were
rotated at room temperature for 20 min. The Streptavidin M-280 magnetic beads
were washed twice in each of the following three buffers: high salt buffer (2 M
NaCl, 50 mM Tris·HCl pH 7.4, 0.5% Triton X-100), binding buffer (above), and low
salt buffer (5 mM Tris·HCl pH 7.4, 0.1% Triton X-100). Beads were resuspended in
TRIzol Reagent (ThermoFisher) and heated at 65°C for 5 min twice to elute the RNA
from the beads. A subsequent ethanol precipitation was performed for RNA purifi-
cation. Nascent RNA was resuspended in 10 µM of the VRA3 3′ end adapter (Table
5.3). 3′ end ligation was performed using T4 RNA ligase I (NEB) for 2 hours at room
temperature. A second Streptavidin M-280 magnetic bead binding was performed
to enrich for ligated nascent RNAs. The beads were subsequently washed twice in
high, binding, and low salt buffers, then once in 1X ThermoPol Buffer (NEB). To pre-
pare nascent RNAfor 5′ end adapter ligation, the 5′ ends of the RNAwere decapped
and repaired. 5′ end decapping was performed using RNA 5′ Pyrophosphohydro-
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lase (NEB) at 37°C for 1 hour. The beads were washed once in high and low salt
buffer, then once in 1X T4 PNK Reaction Buffer (NEB). Samples were treated with
T4 Polynucleotide Kinase (NEB) for 1 hour at 37°C for 5′-hydroxyl repair. Next, T4
RNA ligase I (NEB) was used to ligate the reverse 5′ RNA adapter VRA5 (Table 5.3)
as described previously. Following the 5′ end ligation, beads were washed twice in
high, binding, and low salt buffers, then once in 0.25X FS Buffer (ThermoFisher).
Reverse transcription was performed using Superscript IV Reverse Transcriptase
(ThermoFisher) with 25 ρmol of the Illumina TRU-seq RP1 Primer (Table 5.3). The
RT product was eluted from the beads by heating the samples twice at 95°C for
30 seconds. All libraries were amplified by 12 cycles of PCR with 12.5 ρmol of Il-
lumina TRU-seq RPI-index primers, excess RP1 primer, and Phusion Polymerase
(NEB). The amplified library was purified using the ProNex Size-Selective Purifica-
tion System (Promega) and sequenced using NextSeq 500 machines in a mid-output
150 bp cycle run.
2.8.3 PRO-seq Data Preprocessing
Cutadapt was used to trim paired-end reads to 40 nt, removing adapter sequence
and low quality 3′ ends, and discarding reads that were shorter than 20 nt with
settings -m20 -q 1. Additionally, in order to align reads using Bowtie, 1 nt was
removed from the 3′ end of all trimmed reads. Trimmed paired-end reads were
first mapped to the Drosophila dm3 reference genome using Bowtie, and subse-
quent uniquely mapped reads to the dm3 genome were used to determine percent
spike-in return across all samples. Paired-end reads that failed to align to the dm3
genome were mapped to the mm10 reference genome. Read alignment to the dm3
and mm10 genomes were performed with settings -k1 -v2 -best -X1000 --un.
SAM files were sorted using samtools. Read pairs uniquely aligned to the mm10
genome were separated, and strand-specific single nucleotide bedGraphs of the 3′
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end mapping positions, corresponding to the biotinylated RNA 3′ end, were gener-
ated. Due to the “forward/reverse” orientation of Illumina paired-end sequencing,
“+” and “-” stranded bedGraph files were switched at the end of the pipeline (Ma-
hat et al., 2016). bedGraph files across replicates in each cell treatment were merged
by summing the read counts per nucleotide position. Since the spike-in return was
comparable between biological replicates within a treatment type, and no compar-
isons were made between the two treatment conditions, no further normalizations
were performed.
2.8.4 PRO-seq and Total RNA-seq Data Analysis
A list of active transcripts in MEL cells was first generated using PRO-seq signal
within a 300 nt window around annotated TSSs in the GENCODE mm10 vM20
annotation. Intron annotations that did not correspond to an actively expressed
transcript and had zero spliced read counts, suggesting no evidence of the intron’s
usage in MEL cells, were removed. Additionally, if two intron annotations shared
a 5′SS or 3′SS, the annotation with the most spliced reads was kept. Additionally,
if introns shared both a 5′SS and 3′SS, the intron with the lowest annotated intron
number was kept. Finally, first intron annotations were removed for Figure 3.12
and metagene plots. For all other metagene analyses, introns within 750 nt of a
TSS, and introns with fewer than 10 reads were also filtered out from the final
list of unique introns to avoid bleed-through PRO-seq signal from the promoter-
proximally paused Pol II. Metagene plots around the TSS, splice sites, and PAS
were generated by plotting the average PRO-seq reads (of three biological repli-
cates) in uninduced cells at each indicated position with respect to the TSS, 5′SS,
3′SS, or PAS respectively. Violin plots evaluating PRO-seq 3′ end or RNA-seq read
coverage were generated by summing the signal at the indicated positions with
respect to the 5′SS, 3′SS, or PAS. P-values were calculated using either the Mann-
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Whitney or the Wilcoxon matched-pairs signed rank test
In order to extract PRO-seq reads that were spliced, filtered and trimmed PRO-
seq reads were mapped to the mm10 reference index using STAR with the following
changes to default settings: --outMultimapperOrder Random --outFilterType
BySJout -alignSJoverhangMin 8 --outFilterIntronMotifs
RemoveNoncanonicalUnannotated. All reads in BAM format were filtered for reads
that contained an “N” in their CIGAR string using pysam. Resulting reads were
filtered to discard reads with an “N” size > 10,000 using pysam to remove poorly
mapped reads or reads mapped across very large introns. In all analysis except
where noted, PROs-seq data are represented as three biological replicates com-
bined.
2.9 Data and Code Availability
Raw and processed long-read sequencing and PRO-seq data generated in this the-
sis are deposited in NCBI’s Gene Expression Omnibus and are accessible through
GEO Series accession number GSE144205. Raw image data associated with this
manuscript are available on Mendeley (http://dx.doi.org/10.17632/5vrtbpnj4k.
1). All code supporting the long-read sequencing data analysis is available at https:
//www.github.com/NeugebauerLab/MEL_LRS. NanoCOP data from (Drexler et al.,
2020) analyzed in this thesis can be found at GEO with accession number GSE123191,
and total RNA-seq from MEL cells analyzed in this thesis can be found at Mouse




Regulates 3′-End Cleavage During
Mammalian Erythropoiesis
3.1 PacBio Long-Read Sequencing of Nascent RNA
Yields High Read Coverage
Murine erythroleukemia (MEL) cells are immortalized at the proerythroblast stage
and can be induced to enter terminal erythroid differentiation by treatment with
2% DMSO for five days (Antoniou, 1991). Phenotypic changes include decreased
cell volume, increased levels of β-globin, and visible hemoglobinization (Figure
3.1 A-C). I used chromatin purification of uninduced and induced MEL cells to
enrich for nascent RNA. Chromatin purification under stringent washing condi-
tions allows release of contaminating RNAs and retains the stable ternary complex
formed by elongating Pol II, DNA, and nascent RNA (Figure 3.1 D); Wuarin and
Schibler (1994). Importantly, spliceosome assembly does not continue during chro-
matin fractionation or RNA isolation, because the presence of the splicing inhibitor
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Figure 3.1: DMSO treatment induces erythroid differentiation.
(A) MEL cells after culturing in 2% DMSO for 0, 4, or 6 days. (B) Bright field mi-
croscopy of MEL cells uninduced (left) and induced for 5 days (right). Scale bar is 1
mm. (C) RT-qPCR measurement of Hbb-b1 (β-globin) mRNA levels relative to Gapdh
mRNA from total RNA in MEL cells treated with 2% DMSO for 0, 2, 4, or 6 days.
Bar heights represent mean of 3 technical replicates, and error bars represent SEM.
(D) Western blot of subcellular fractions collected during chromatin fractionation
(CYT = cytoplasm, NPL = nucleoplasm, CHR = chromatin).
To generate libraries for LRS, I established the protocol outlined in Figure 3.3.
Two biological replicates, each with two technical replicates, were sequenced us-
ing PacBio RSII and Sequel flow cells, yielding a total of 1,155,629 mappable reads
(Table 5.2). Reads containing a non-templated polyA tail comprised only 1.7% of
the total reads (Table 5.2) and were removed bioinformatically along with abun-
dant 7SK RNA reads. Of the remaining reads, the average read length was 710 and
733 nucleotides (nt), and the average coverage in reads per gene was 8.4 and 4.8 for
uninduced and induced samples, respectively (Figure 3.4 A-B). More than 7,500
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1 μM PladB treatment in cell culture:
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Figure 3.2: Splicing does not continue during chromatin purification and
nascent RNA isolation.
(A) RT-PCR on total RNA collected from MEL cells treated with 1 µM splicing in-
hibitor Pladienolide B in cell culture for 0, 1, 2, and 4 hours. Total RNA was re-
verse transcribed with random hexamers, and PCR primers span a single intron in
each gene. Three representative genes are shown (left: Brd2, middle: Dnajb1, and
right: Riok3). M indicates mock treatment with DMSO, and G indicates amplifi-
cation of genomic DNA to determine the size of unspliced RNA. U indicates size
of unspliced amplicon, and S indicates size of spliced amplicon. (B) RT-PCR from
total RNA as in (A), showing six additional genes (Slc12a6, Dmtn, Hnrnpll, Rbm39,
Hbq1b, C1qbp) after treatment with 1 µM Pladienolide B for 0 h and 4 h. (C) RT-PCR
on nascent RNA isolated from chromatin which was fractionated in the absence (-)
or presence (+) of 1 µM Pladienolide B. Nascent RNA was reverse transcribed with
random hexamers and PCR primers were the same as in (A) and (B).
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3.4 B). Coverage of 5′ ends was focused at annotated transcription start sites (TSSs),
with 18.3% of 5′ ends within 50 bp of an active TSS across all samples. As expected,
3′ end coverage was distributed more evenly throughout gene bodies, with an in-
















Figure 3.3: Long-read sequencing library preparation workflow.
Schematic of nascent RNA isolation and sequencing library generation. MEL cells
are treated with 2% DMSO to induce erythroid differentiation, cells are fraction-
ated to purify chromatin, and chromatin-associated nascent RNA is depleted of
polyadenylated and ribosomal RNAs. An adapter is ligated to the 3′ ends of re-
maining RNAs, then a strand-switching reverse transcriptase is used to create
double-stranded cDNA that is the input for PacBio library preparation.
3.2 LRS Reveals Widespread Co-transcriptional
Splicing
Each long-read provides two critical pieces of information: the 3′ end reveals the
position of Pol II when the RNA was isolated; the splice junctions reveal if splicing

































Figure 3.4: Long-read sequencing library length and depth distributions.
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Figure 3.5: Long-read sequencing library metagene coverage.
Normalized read coverage (RPKM) of long-read 5′ ends (left), full reads (middle),
and 3′ ends (right) is shown across a metagene plot of all mm10 genes +/- 1 kb (TSS
= transcription start site, TES = transcription end site).
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a format that highlights 3′ end position and the associated splicing status (Figure
3.6 A). Each transcript was categorized and coloured according to its splicing sta-
tus, which can be either “all spliced”, “partially spliced”, “all unspliced”, or “NA”
(transcripts that did not span an entire intron or a 3′SS). For each gene, I calculated
the fraction of long-reads that were all spliced, partially spliced, or all unspliced
(Figure 3.6 A; bar plot far right), enabling a survey of splicing behaviors within in-
dividual transcripts (Alpert et al., 2020; Herzel et al., 2018; Kim and Abdel-Wahab,
2017).
Splicing status of individual transcripts varied from gene to gene. For example,
the gene Actb had mostly all spliced reads (78% and 75% of reads in uninduced
and induced cells respectively), while Calr and Eif1 had a greater fraction of all
unspliced reads (Figure 3.6 B). Genome-wide, the majority of long-reads were all
spliced (Figure 3.7 A; 68.0% and 73.8% for uninduced and induced cells, respec-
tively), with an average of 88% of all introns being spliced. Therefore, the majority
of introns are removed co-transcriptionally. To validate this finding, I examined
the read length distribution for reads of each splicing status (Figure 3.7 B). As ex-
pected, partially spliced and all unspliced reads were on average longer than all
spliced reads due to the presence of introns, suggesting that the efficient shorten-
ing of nascent RNA due to splicing limits the lengths of long-reads.
To quantify co-transcriptional splicing for each intron detected by at least 10
long-reads, I defined a metric termed the Co-transcriptional Splicing Efficiency
(CoSE), tabulated as the number of spliced reads that span the intron divided by
the total number of reads (spliced + unspliced) that span the intron (Figure 3.8 A). A
higher CoSE value indicates a higher fraction of co-transcriptional splicing. To val-
idate this metric, I analyzed an independently generated total RNA-seq dataset in
uninduced MEL cells (downloaded from ENCODE; (Davis et al., 2018)). Although
nascent RNA is rare in total RNA, the density of reads mapping to a given intron
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Figure 3.6: Nascent RNA long-read sequencing reveals widespread
co-transcriptional splicing.
(A) LRS data visualization for analysis of co-transcriptional splicing. Gene diagram
is shown at the top, with the black arrow indicating the TSS. Reads are aligned to the
genome and ordered by 3′ end position. Colour code indicates the splicing status
of each transcript. Each horizontal row represents one read. Panels at far right and
below: regions of missing sequence (e.g. spliced introns) are transparent. Light
gray shading indicates regions of exons, and dark gray shading indicates the region
downstream of the annotated PAS (dotted red line). The number of individual long-
reads aligned to each gene (n) is indicated. Bar graph at the far right of each plot
indicates the fraction of reads that are all spliced (dark purple), partially spliced
(light purple), or all unspliced (yellow) for that gene. (B) LRS data are shown for
uninduced (top) and induced (bottom) MEL cells for three representative genes:

































Figure 3.7: Distributions of all spliced, partially spliced, and all unspliced
long-reads.
(A) Fraction of long-reads genome-wide that are all spliced, partially spliced, or all
unspliced (n = 120,143 reads uninduced, n = 71,639 reads induced). (B) Long-read
length distribution separated by splicing status (n = 134,857 all spliced reads, n =
23,833 partially spliced reads, n = 35,957 all unspliced reads).
is expected to be inversely proportional to splicing efficiency. The ratio of intron-
mapping reads relative to the flanking exon-mapping reads was calculated for each
intron and compared to CoSE levels. As expected, higher CoSE corresponded to
lower relative intron coverage in the total-RNA seq data (Figure 3.9 A). Thus, this
independent data set validates the CoSE metric. CoSE values also remained stable
across all levels of read coverage (Figure 3.9 B).
To determine if intron splicing events are coordinated within the same tran-
script, I asked how similar CoSE values were between introns in the same tran-
script. To do so, transcripts containing at least 3 introns with recorded CoSE values
(n = 2,028) were compiled. I found that the variance in CoSE between introns within
the same transcript was significantly smaller than the variance in CoSE for the same
number of randomly assorted introns (Figure 3.8 B). Taken together, these results
suggest that most introns are well-spliced co-transcriptionally, and that splicing is
coordinated in mammalian multi-intron transcripts expressed by both uninduced
and induced MEL cells.
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Figure 3.8: Individual mammalian nascent RNA sequences reveal coordination
of co-transcriptional splicing.
(A) For each intron that is covered by 10 or more reads, CoSE is defined as the
number of reads that are spliced divided by the total number of reads that span the
intron. (B) Variance in CoSE for transcripts that include 3 or more introns covered
by at least 10 reads (n = 1,240 transcripts uninduced, n = 788 transcripts induced)
compared to the variance in CoSE for a randomly selected group of introns. Signif-





























































Figure 3.9: CoSE values agree with total RNA-seq and remain stable across
intron coverage levels.
(A) Intron coverage relative to flanking exon coverage from untreated MEL total
RNA-seq Illumina data (ENCODE) is shown as an independent indicator of un-
spliced RNA levels. Introns that were covered by at least 10 long-reads in the un-
treated condition were split into bins based on the CoSE metric calculated from
long-read sequencing data. Significance tested by Mann Whitney U-test; *** rep-
resents p-value ¡0.001. (B) CoSE values as a function of the number of long-reads
covering each intron. Each point represents an intron for which a CoSE value was
calculated, with uninduced and induced data shown combined (n = 14,422 introns).
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3.3 Co-transcriptional Splicing Occurs Rapidly After
Intron Transcription
The frequency of all-spliced nascent transcripts implies that splicing in mammalian
cells is rapid enough to match the rate of transcription. A direct way to address
this is to measure the position of Pol II on nascent RNA when ligated exons are
observed. Observing Pol II downstream of a spliced junction indicates that the ac-
tive spliceosome has assembled and catalyzed splicing in the time it took for Pol II
to translocate the measured distance. Therefore, I determined the distance in nu-
cleotides between the 3′ end of each read and the nearest spliced exon-exon junction
(Figure 3.10 A). To eliminate 3′ ends that arise from splicing intermediates and not
from active transcription, reads with 3′ ends mapping precisely to the last nt of
exons were removed from this analysis. Although the longest distances between
splice junctions and elongating Pol II were just over 6 kb, these were rare. Instead,
75% of splice junctions were within 300 nt of a 3′ end, and the median distance
was 154 nt in uninduced cells and 128 nt in induced cells (Figure 3.10 B). There-
fore, changes in the gene expression program during erythropoiesis did not alter
the dynamic relationship between transcription and splicing. Consistent with this,
CoSE values were similar when comparing induced to uninduced cells (Figure 3.10
C; Spearman’s rho = 0.56). In fact, only 66 introns with improved splicing, and 42
introns with reduced splicing displayed > 2-fold change in CoSE upon induction.
Taken together, these results show that although global changes in gene expression
occur between these two timepoints, the relationship between transcription and
splicing remains the same. Overall, these two measurements do not support major
changes in splicing efficiency during erythroid differentiation. Moreover, the dis-
tance from Pol II to the nearest splice junction was independent of GO category or
intron length (Figure 3.11 B; GO analysis not shown). Because median exon size
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in the mouse genome is 151 nt (Waterston et al., 2002), my data indicate that ac-
tive spliceosomes can be fully assembled and functional when Pol II is within or
just downstream of the next transcribed exon. Recent direct sequencing of nascent
RNA seemed to reveal less rapid splicing (Drexler et al., 2020). However, when I
analyzed this dataset in the same manner as my own, the cumulative distance from
Pol II to the nearest splice junction is similarly close across organisms and cell types
(median distance in human BL1184 = 244 nt, human K562 = 310 nt, Drosophila S2
= 335 nt; Figure 3.11 A). Thus, I conclude that efficient and coordinated splicing are
a general property of metazoan gene expression.
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Figure 3.10: Spliceosome-Pol II proximity is unchanged by differentiation.
(A) Schematic definition of the distance from the 3′ end of a nascent RNA (nRNA)
to the most 3′-proximal splice junction. 3′ end sequence reports the position of Pol II
when nascent RNA was isolated. (B) Distance (nt) from the 3′-most splice junction
to Pol II position is shown as a cumulative fraction for uninduced and induced cells
(n = 101,911 observations uninduced, n = 66,656 induced). (C) CoSE in induced and
uninduced conditions. Each point represents a single intron which is covered by at
least 10 long-reads in both induced and uninduced conditions. Spearman’s rho =
0.56, n = 4,170 introns.
3.4 Pol II Does Not Pause at Splice Sites for Splicing
to Complete
Note: PRO-seq experiments and analysis in sections 3.4 - 3.6 were performed in collabora-
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Figure 3.11: Pol II is detected near splice junctions in multiple cell types.
(A) Distance (nt) from the most 3′-proximal splice junction to Pol II position is
shown as a cumulative fraction. Analysis is the same as in Figure 3.10, but with
data from this study and nanoCOP data from Drexler et al. (2020) (n = 39,397 reads
in BL1184 cells, n = 183,829 reads in K562 cells, n = 68,956 reads in S2 cells, and n
= 168,567 reads in MEL cells). (B) Distance (nt) from the most 3′-proximal splice
junction to Pol II position is shown categorized by upstream intron length in three
equal-sized bins (short = 30 nt – 443 nt, med = 443 nt – 1,738 nt, long >= 1,738
nt). Significance tested by Mann Whitney U-test: *** represents p-value < 0.001, ns
represents p-value > 0.05.
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One explanation for the relatively short distances observed between splice junc-
tions and Pol II may be that Pol II pauses just downstream of an intron, allowing
time for splicing to occur before elongation continues. Alternatively, Pol II could
pause at the end of the downstream exon. This model has been proposed as a mech-
anism for splicing and transcription to feedback on each other, with pausing pro-
viding a possible checkpoint for correct RNA processing (Alexander et al., 2010b;
Carrillo Oesterreich et al., 2011; Chathoth et al., 2014; Milligan et al., 2017). How-
ever, the conclusions of recent work have disagreed on the behavior of Pol II elonga-
tion near splice junctions, with some studies indicating long-lived pausing at splice
sites, and others reporting no significant pausing (Kwak et al., 2013; Mayer et al.,
2015; Sheridan et al., 2019). To resolve this controversy, we measured changes in
elongating Pol II density genome-wide using Precision Run-On sequencing (PRO-
seq) in MEL cells. PRO-seq maps actively elongating Pol II complexes at single-
nucleotide resolution by incorporating a single biotinylated NTP (Mahat et al.,
2016). Comparing PRO-seq with LRS is advantageous, because PRO-seq data pro-
vide an independent measure of nascent RNA 3′ ends that are undergoing active
elongation; these 3′ ends cannot originate from other chromatin-associated inter-
mediates, such as splicing intermediates.
We analyzed our PRO-seq data to determine if transcription elongation behav-
ior changes across intron-exon boundaries. Because both induced and uninduced
LRS datasets showed an overlapping distribution of Pol II when spliced products
are observed, we initially combined the PRO-seq datasets. As expected, metagene
plots around active TSSs revealed prominent promoter-proximal pausing (Figure
3.12 A); (Core and Adelman, 2019). Analyzing PRO-seq signal around splice sites
initially revealed a small peak near the 5′SS. To control for the possibility that high
PRO-seq density from TSS peaks might bleed through to the first 5′SS, first introns
were independently analyzed. Indeed, elevated PRO-seq signal in the vicinity of
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5′SSs was only seen at first introns, and only at introns with 5′SS<= 250 nt from the
TSS (Figure 3.13 A). Interestingly, middle introns showed a similar profile to termi-
nal introns, both lacking increased PRO-seq signal around splice sites (Figure 3.13
B). Accordingly, after removal of first introns from our analysis, PRO-seq signal
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Figure 3.12: Pol II does not pause at 5′ or 3′ splice sites.
(A) PRO-seq 3′ end coverage is shown aligned to active transcription start sites
(TSS), 5′ splice sites (5′SS), and 3′ splice sites (3′SS). (B) Left: Schematic illustrating
the use of colour-coded intervals to quantify PRO-seq reads around each 5′SS and
3′SS to test for significance of pausing. Right: PRO-seq read density summed in
each of the intervals indicated at left around 5′SSs (left) and 3′SSs (right) from in-
trons with at least 10 reads in uninduced conditions (n = 3,505). Significance tested
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Figure 3.13: PRO-seq reveals no Pol II pause at any subset of introns.
(A) PRO-seq 3′ end coverage aligned to 5′SSs for all introns (dark purple), introns
where the distance from the TSS to the 5′SS is <= 250 nt (light purple), and introns
where the distance to the TSS to the 5′SS is > 250 nt (light orange). Right panel
shows data scaled to show all introns. (B) PRO-seq 3′ end coverage aligned to 5′SSs
for all introns from active transcripts (dark purple), first introns only (light purple),
middle introns (light orange), and terminal intron (dark orange). Right panel shows
data scaled to show all introns. (C) Average PRO-seq 3′ end coverage is shown
around 5′SS (left) and 3′SS (right) for introns in each CoSE category as indicated. N
= number of introns in each category.
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3.5 Statistical Methods for Evaluating Pol II Pausing
The depth of our PRO-seq libraries enabled us to determine if these minor fluc-
tuations in PRO-seq signal were statistically significant. To do so, we compared
summed PRO-seq read counts in three windows surrounding each intron/exon
junction for uninduced cells only (Figure 3.12 B; left): -150 to -50 nt upstream of
the junction, -40 to +10 nt spanning the junction, and +50 to +150 nt downstream
of the junction. Comparing the signal between the upstream window and 5′SS-
spanning window indicated no statistically significant increase in PRO-seq read
density (paired t test p> 0.05). In contrast, a significant decrease in PRO-seq signal
is observed as Pol II moves from the exon into the intron (p < 0.0001; comparing
upstream to downstream window at the 5′SS), consistent with data showing faster
transcription rates within introns (Jonkers et al., 2014; Veloso et al., 2014). Interest-
ingly, we observe a dip in PRO-seq signal right before the 3′SS (p< 0.0001), instead
of a peak of Pol II consistent with pausing. Although the cause of this dip remains
to be determined, it is unlikely to represent Pol II arrest and/or termination near
this junction because signal downstream of the 3′SS does not decrease. In sum-
mary, we can detect significant changes in Pol II elongation behavior as it moves
from exon to intron and vice versa, but we find no evidence for significant pausing
at splice junctions.
To rigorously compare splicing efficiency to Pol II elongation behavior, we eval-
uated PRO-seq signals around introns binned by CoSE values from our LRS data.
Again, we observed no significant differences in Pol II profile around splice sites
within any group of introns (Figure 3.13 C). Interestingly, the overall level of PRO-
seq coverage is lower in transcripts with higher CoSE values, suggesting that lowly
expressed transcripts might be more efficiently spliced. Finally, a number of PRO-
seq reads contained spliced junctions despite the short read lengths (Figure 3.14;
396,257 spliced reads out of 289,610,781 total mapped reads). These data confirm
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that mammalian splicing can occur when actively engaged Pol II is just down-
stream of the 3′SS, within a median distance of 128-154 nt. Taken together, two
complementary methods to probe Pol II position and splicing status indicate that








Figure 3.14: Spliced PRO-seq reads confirm co-transcriptional splicing.
Genome browser view showing spliced PRO-seq reads aligned to the Apbb1 gene,
where 3′ ends of reads represent the position of elongating Pol II. Only spliced
reads, filtered from all reads, are shown.
3.6 Splicing Intermediates Are Abundant for a Subset
of Introns
I expected to readily observe transient splicing intermediates in my nascent RNA
libraries, because the two-step transesterification reaction yields a 3′-OH at the end
of the upstream exon after step I (Figure 3.15 A). Indeed, splicing intermediates
have previously been observed using other chromatin-associated RNA sequenc-
ing methods (Burke et al., 2018; Chen et al., 2018; Churchman and Weissman, 2011;
Nojima et al., 2015, 2018). As expected, I observed elevated 3′ end coverage pre-
cisely at the last nucleotide of exons (Figure 3.15 B), with these first step splicing
intermediate reads accounting for 7.0% of the data (Table 5.2). The rarity of splic-
ing intermediates detected agrees with my finding that splicing does not continue
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during chromatin fractionation or RNA isolation (Figure 3.2).
Nevertheless, a small number of genes contained a large number of splicing
intermediates at a single intron within the gene (Figure 3.15 C and D). For ex-
ample, 216 of the 433 reads mapped to Alas2 had 3′ ends mapped to the end of
exon four (Figure 3.15 D and Figure 3.16 A). I note that several reads (16/433)
mapping to Alas2 were one of the extremely rare instances of potential recursive
splicing. In this case, I observed an unannotated splice junction which generated a
new 5′SS immediately adjacent, with the junction sequence cagGUAUGU (Figure
3.16 B). Although I observed no other compelling instances of recursive splicing
in my dataset, I note that recursive splicing has been previously characterized in
extremely long introns, which are difficult to detect using my methods (Pai et al.,
2018; Sibley et al., 2015). Nevertheless, I conclude that recursive splicing could oc-
cur co-transcriptionally.
To determine what features of specific introns might lead to increased splicing
intermediates, I counted and normalized the number of splicing intermediates ob-
served for each intron. The normalized intermediate count (NIC), is defined as the
number of splicing intermediate reads at the last nt of the exon divided by the sum
of splicing intermediate reads and spliced reads. This metric reports the fraction
of long-reads that are captured between step I and step II of splicing. All unique
introns which were covered by at least 10 long-reads were binned based on their
observed NIC value, and the splice site strength of the introns in each bin was cal-
culated using the MaxEnt algorithm (Yeo and Burge, 2004). While the 5′SS score
was relatively constant, introns with the highest NIC value tended to have lower
5′SS and 3′SS scores (Figure 3.17 A). Intron length or GC-content showed no similar
trend (Figure 3.17 B and C).
Finally, I tested whether or not spliceosomal stalling between steps I and II could
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Figure 3.15: Splicing intermediates are detected at a subset of introns.
(A) Schematic definition of first step splicing intermediates (dotted red oval), which
have undergone the first step of splicing and have a free 3′-OH that can be ligated
to the 3′ end DNA adapter. Splicing intermediate reads are characterized by a 3′
end at the last nucleotide of the upstream exon. (B) Coverage of long-read 3′ ends
(top panels) and 5′ ends (bottom panels) aligned to 5′SSs (left) and 3′SSs (right) of
introns. (C) Histogram showing frequency of splicing intermediates upstream of
each unique intron from active transcripts in MEL cells. Most introns show 0 or 1
splicing intermediates, while some introns, like those in Alas2 and Hmbs, indicated
with orange arrows, exhibit over 150 splicing intermediates reads. (D) Coverage of
long-read 3′ ends across four example genes. Arrows indicate the positions where
the most abundant splicing intermediates are observed.
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Figure 3.16: Instance of recursive splicing at Alas2.
(A) Individual long-reads are shown for the gene Alas2. Diagram is similar to Fig-
ure 3.6, but individual reads are coloured depending on whether they are splicing
intermediates (purple) or not (gray). Data for uninduced and induced cells are
shown combined. Potential recursive splicing site is indicated by an arrow and
dotted line. (B) Recursively spliced reads from (A) are shown in detail.
associated 3′SSs. Note that PRO-seq signal was universally higher in introns with 1
or more splicing intermediates as was total RNA-seq density in flanking exons, in-
dicating that these genes were more highly expressed (Figure 3.18 B and C). How-
ever, no differences in Pol II density were detected around 3′SS between introns
with NIC = 0 and NIC > 0 (Figure 3.18 A). Based on these data, we suggest that
introns with weak 3′SSs experience a delay between the catalytic steps of splicing
without an associated delay in transcription.
3.7 Unspliced Transcripts Display Poor Cleavage at
Gene Ends
Consistent with physiological terminal erythroid differentiation, my induced MEL
cells shifted to maximal expression of α- and β-globin genes, each containing two
introns. Markedly increased numbers of long-reads mapped to the β-globin (Hbb-
b1) locus were detected, in agreement with increased β-globin mRNAlevels (Figure
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Figure 3.17: Introns with weak 3′SSs accumulate splicing intermediates.
(A) MaxEnt splice site scores for 5′SS (left) and 3′SS (right) for introns with a cover-
age of at least 10 long-reads is shown categorized by the normalized intermediate
count (NIC) at each intron. Introns with NIC = 0 (n = 3,890) are shown separately,
and all other introns with NIC > 0 (n = 2,647) are separated in quartiles with NIC
values shown. (B) Intron length (nt) and (C) intron GC-content for unique introns
from active transcripts categorized by NIC value. Introns with NIC = 0 (n = 3,890)
are shown separately, and all other introns with NIC > 0 (n = 2,647) are separated
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Figure 3.18: Pol II pausing is not assoicated with a delay in catalytic steps of
splicing.
(A) Raw PRO-seq 3′ end coverage from uninduced cells aligned to 5′SSs, and 3′SSs
for introns with NIC = 0 (n = 4,402), or NIC > 0 (n = 3,427). (B) PRO-seq and (C)
Total RNA-seq (ENCODE) reads summed within the upstream and downstream
exons surrounding each intron containing 10 or more long-reads in the uninduced
condition and normalized by exon length for introns with NIC = 0 (dark purple) or
NIC > 0 (light purple).
3.19 A; Figure 3.1 C). To my surprise, a large fraction of individual β-globin long-
reads in the induced condition had 3′ ends that mapped up to 2.5 kb downstream of
the annotated polyA site (PAS), indicating that these transcripts failed to undergo
3′ end cleavage at the PAS. Pol II occupancy past the β-globin PAS was confirmed
by PRO-seq (Figure 3.19 B). Notably, PRO-seq reads are commonly detected well
past the gene 3′ ends due to transcription termination (Core et al., 2008). However,
my LRS data indicate significant transcription past the polyA cleavage site in the
absence of 3′ end cleavage, which cannot be revealed by PRO-seq. Remarkably, the
β-globin transcripts that escaped 3′ end cleavage were almost uniformly unspliced
(Figure 3.19 A). The α-globin genes (Hba-a1 and Hba-a2) displayed a similar phe-
nomenon (Figure 3.20 A-C). Thus, a significant fraction of nascent globin RNAs
undergo “all or none” RNA processing under these conditions of erythroid differ-
entiation: either both introns are efficiently spliced and the nascent RNA is cleaved
at the 3′ end or, conversely, both introns are retained and the nascent RNA is inef-
ficiently cleaved.
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Figure 3.19: Poor splicing efficiency is associated with inefficient 3′ end
cleavage.
(A) Individual long-reads are shown for the major β-globin gene (Hbb-b1). Diagram
is as described in Figure 3.6. (B) LRS coverage (orange) and PRO-seq 3′ end cover-
age (purple) in induced cells is shown at the Hbb-b1 gene. Scale at the left indicates
coverage in number of reads, and red dotted line indicates PAS. Note that the dupli-
cated copies of β-globin in the genome (Hbb-b1 and Hbb-b2) impedes unique map-
ping of short PRO-seq reads in the coding sequence, artificially reducing gene body
reads. (C) Fraction of uncleaved long-reads (top) and all other long-reads (bottom)
categorized by splicing status (as described in Figure 3.6). Uncleaved reads have
a 5′ end within an actively transcribed gene region and a 3′ end greater than 50
nt downstream of the PAS (n = 5,694 uncleaved long-reads, and n = 172,612 other
long-reads). (D) Long-read coverage in the region downstream of PASs is shown
for long-reads separated by their splicing status. Coverage is normalized to the
position 100 nt upstream of each PAS (n = 35,982 all unspliced reads, n = 24,102





















































































Figure 3.20: α-globin genes exhibit unspliced transcripts that are uncleaved and
extend past the PAS.
(A) Individual long-reads are shown for the α-globin 1 gene (Hba-a1) and α-globin
2 gene (Hba-a2). Diagrams are as described in Figure 3.6. (B-C) PRO-seq 3′ end read
coverage is shown downstream of the Hba-a1 (B) and Hba-a2 (C) gene loci. Note
that the duplicated copies of α-globin in the genome (Hba-a1 and Hba-a2) impedes
unique mapping of short PRO-seq reads in the coding sequence, artificially reduc-
ing the density of gene body reads. Red dotted line indicates PAS. Data represent
three biological replicates combined. (D) Summed PRO-seq signal in the region 1
kb downstream of the PAS in uninduced cells. Introns were binned by CoSE values,
then the PRO-seq read coverage was calculated for each intron and counted only
once per bin. Significance tested by Mann-Whitney U-test; *** represents p-value ¡
0.001, ns represents p-value > 0.05
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Because other genes showed evidence of all-or-none splicing (Figure 3.6 B), a
correlation between splicing and cleavage at the PAS was examined globally. To
do so, I categorized long-reads as uncleaved if the 5′ end originated within a gene
body and the 3′ end mapped more than 50 nt downstream of an annotated PAS. In
comparison to all other long-reads, uncleaved long-reads were 2.5-fold more likely
to be unspliced (Figure 3.19 C). Next, I analyzed long-read coverage downstream
of annotated PASs for reads with different splicing statuses. Coverage of all un-
spliced reads was globally higher in the region downstream of a PAS than it was
for partially spliced or all spliced reads (Figure 3.19 D). PRO-seq data support this
observation, with significantly less PRO-seq signal observed in the region down-
stream of the PAS for transcripts harboring introns with the highest CoSE values
(Figure 3.20 D). This genome-wide decrease in splicing efficiency associated with
impaired 3′ end cleavage confirmed the coordination between splicing and 3′ end
processing prominently observed in the globin genes.
3.8 A β-thalassemia Mutation Enhances Splicing and
3′ End Cleavage Efficiencies
To investigate how mutations in splice sites alter co-transcriptional splicing effi-
ciency, I took advantage of a known β-thalassemia allele. A patient-derived G>A
mutation in intron 1 of human β-globin (HBB) leads to new AG dinucleotide in in-
tron 1, creating a cryptic 3′SS 19 nt upstream of the canonical 3′SS (Figure 3.21 A).
This thalassemia-causing mutation, known as IVSI-110, generates an HBB mRNA
with an in-frame stop codon, resulting in a 90% reduction in functional HBB pro-
tein through nonsense-mediated decay (Spritz et al., 1981; Vadolas et al., 2006). I
utilized two MEL cell lines expressing either an integrated copy of a human β-
globin minigene (MEL-HBBWT) or the human β-globin minigene with the IVSI-110
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mutation (MEL-HBBIVS-110(G>A)) (Patsali et al., 2018). Specific targeting of these inte-
grated human HBB loci during library preparation resulted in an average of 24,970
nascent RNA long-reads that mapped to the HBB gene for each of 3 biological repli-
cates (Table 5.2), allowing rigorous statistical analysis. As previously reported, the
majority (94%) of intron 1 splicing in the MEL-HBBIVS-110(G>A) cell line occurred at
the cryptic 3′SS.
MEL-HBBIVS-110(G>A) cells exhibited a significant increase in the fraction of long-
reads that were all spliced and a corresponding decrease in long-reads that were all
unspliced (Figure 3.21 B). The low co-transcriptional splicing efficiency detected for
endogenous mouse β-globin was mirrored in the stably integrated HBB minigene,
where 80-92% of long-reads were all unspliced (compare Figures 3.19 A and 3.21
B). Long-reads with only intron 1 spliced were present at a higher ratio in the MEL-
HBBWT cells, whereas long-reads with only intron 2 spliced were more frequent in
the MEL-HBBIVS-110(G>A) cells. This distribution suggests that the cryptic intron 1
is spliced more efficiently than the WT intron 1, leading to a coordinated increase
in splicing of intron 2 and a shift from all unspliced to all spliced reads. This in-
terpretation agrees with the coordinated co-transcriptional splicing efficiency I ob-
served in multi-intron transcripts genome-wide (Figure 3.8 B). Significantly fewer
splicing intermediates were detected for both introns in the MEL-HBBIVS-110(G>A)
cells compared to MEL-HBBWT cells, suggesting that inefficient splicing can lead to
spliceosomal pausing between catalytic steps I and II (Figure 3.21 C).
To rigorously test the possibility that changes in co-transcriptional splicing effi-
ciency determine 3′ end cleavage, read coverage downstream of the HBB PAS was
used to detect uncleaved long-reads for each category of splicing status (Figure
3.21 D). All-unspliced HBB reads were detected up to 4 kb past the PAS, similar
to endogenous mouse globin genes. When only intron 2 was spliced, cleavage in
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Figure 3.21: Efficient splicing promotes 3′ end cleavage.
(A) Top: schematic describing two engineered MEL cell lines. MEL-HBBWT contains
an integrated copy of a wild type human globin minigene. In MEL-HBBIVS-110(G>A),
a single point mutation (red triangle) mimics a disease-causing thalassemia allele.
Bottom: Sanger sequencing of the HBB minigene coding strand shows that a G>A
mutation leads to a cryptic 3′SS at the AG dinucleotide 19 nt upstream of the canoni-
cal 3′SS. (B) Distribution of HBB long-reads in MEL-HBBWT cells (purple) and MEL-
HBBIVS-110(G>A) cells (orange) separated by splicing status of intron 1 and intron 2
and measured as a fraction of total reads mapped to the HBB gene (n = 20,395 reads
in MEL-HBBWT cells, and n = 26,244 reads in MEL-HBBIVS-110(G>A) cells). (C) Frac-
tion of splicing intermediates at intron 1 and intron 2 in MEL-HBBWT cells (pur-
ple) and MEL-HBBIVS-110(G>A) cells (orange) measured as a fraction of total reads
mapped to the HBB gene. For (B-C), significance tested by Mann Whitney U-test;
*** represents p-value < 0.001, bar height represents the mean of three biological
replicates, and error bars represent standard error of the mean. (D) Read cover-
age in the region downstream of the HBB PAS is shown for long-reads separated
by their splicing status from MEL-HBBWT cells (purple) and MEL-HBBIVS-110(G>A)
cells (orange). Coverage is normalized to the position 100 nt upstream of the PAS.
Solid line represents the mean coverage of three biological replicates, and shaded
windows represent standard error of the mean.
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However, a notable decrease in uncleaved reads past the PAS was detected among
transcripts spliced at the cryptic 3′SS as compared to the canonical 3′SS (Figure 3.21
D; center left). When both introns were spliced, there was an even more dramatic
shift to proper cleavage at the PAS in the MEL-HBBIVS-110(G>A) cells (Figure 3.21 D;
far right). Together, these findings confirm my demonstration of functional cou-
pling between splicing and 3′ end formation at the individual transcript level and
highlight the regulatory potential of just a single point mutation. Thus, a previously
unappreciated level of crosstalk between splicing and 3′ end cleavage efficiencies





This study reveals functional relationships between co-transcriptional RNA pro-
cessing events derived from genome-wide analysis of individual nascent transcripts
purified from differentiating mammalian erythroid cells. Transcription and splic-
ing dynamics were visualized with unprecedented depth and accuracy through
long-read sequencing of nascent RNA and PRO-seq. I conclude that splicing catal-
ysis can occur when Pol II is just 75-300 nt past the intron without transcriptional
pausing at the splice sites. Thus, spliceosome assembly and the transition to cataly-
sis often occur when the spliceosome is physically close to Pol II. Two striking cases
stood out from my observations of splicing. First, introns that contain a weak 3′SS
seem to induce stalling between steps I and II of the splicing reaction itself, caus-
ing a buildup of splicing intermediates. Second, inefficient splicing was globally
correlated with inefficient 3′ end cleavage on both the population and single tran-
script level (Figure 4.1). I pursued this second phenomenon further in the context
of globin gene expression, wherein all two-intron globin genes (two α and two β in
mouse) displayed “all-or-none” splicing behavior. Approximately 20% of endoge-
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nous nascent Hbb-b1 transcripts retained both introns and were inefficiently cleaved
at the PAS. Remarkably, a patient-derived, thalassemia-causing point mutation in
β-globin increased splicing efficiency and 3′ end cleavage. These data show that





splicing stall after step 1
at weak 3′SS
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weak 3′SS polyA site
Figure 4.1: Model describing the variety of co-transcriptional splicing
phenomena observed during murine erythropoiesis.
4.2 Conservation of Co-transcriptional Splicing
Mechanisms
The data presented here indicate that the mammalian spliceosome is capable of
assembling and acting on nascent RNA substrates in the same spatial window of
transcription as the yeast spliceosome (Carrillo Oesterreich et al., 2016; Herzel et al.,
2018). This is despite changes in the complexity of yeast and mammalian spliceo-
somes, the length and number of introns in mammals, as well as the number of
accessory factors that can influence splicing. My high resolution determination of
the fraction of splicing that occurs co-transcriptionally (88%) matches data from
alternative methods (e.g. short-read sequencing, metabolic labeling, and imaging)
showing that 75-87% of splicing is co-transcriptional in yeast, fly, mouse, and hu-
man cells (reviewed in Neugebauer (2019)). These findings suggest widely con-
served features of transcription and splicing mechanisms.
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Arecent paper reports that the majority of introns in both human and fly nascent
RNA appear unspliced and that Pol II is 2-4 kb downstream of the 3′SS when splic-
ing occurs (Drexler et al., 2020), which is at odds with my findings. One possible ex-
planation for this discrepancy is that the purification of 4-thiouridine (4sU)-labeled
RNA inadvertently enriched for long, intron-containing RNAs that have a greater
probability of containing a labeled U residue (introns are U-rich). 4sU incorpora-
tion may also impede splicing due to changes in base-pairing among U-rich RNA
elements in introns and snRNAs (Testa et al., 1999). Indeed, direct comparison of
splicing efficiencies with vs. without 4sU-labelling indicates that 4sU-lableled RNA
is less frequently spliced (Drexler et al., 2020). In this context, I note that the prin-
cipal difference between the data from our two labs is the fraction of unspliced
RNAs observed. However, when I analyzed spliced RNAs in the Drexler et al. data
to determine the distance between splice junctions and the RNA 3′ end, I obtained
similar results to my own (Figure 3.11 A). I conclude that splicing more typically
occurs when Pol is close to the intron.
4.3 Pol II Does Not Pause at Splice Junctions
Importantly, PRO-seq corroborated the efficiency of co-transcriptional splicing. We
identified spliced reads within the PRO-seq data, validating the observations made
with LRS of purified nascent RNA by an independent method. Similarly, mNET-
seq data, which are generated by short-read sequencing of nascent RNA from im-
munoprecipitated Pol II, has revealed examples of spliced reads (Nojima et al.,
2018). Having observed many examples wherein an RNA 3′ end was only a short
distance beyond the 3′SS, I considered the hypothesis that Pol II pausing at or near
3′SSs could provide extra time for splicing (Alexander et al., 2010b; Chathoth et al.,
2014; Milligan et al., 2017). However, my analysis shows that any detection of a
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PRO-seq peak at 5′SSs—albeit small in meta-analysis—is caused by bleed-through
from promoter-proximal pausing, and I do not detect statistically significant paus-
ing at 5′ or 3′SSs (Figure 3.12 A, B), in agreement with a recent study using mNET-
seq (Sheridan et al., 2019). Importantly, Pol II elongation was not detectably im-
pacted by the splicing efficiency of introns (Figure 3.13 C), with no significant dif-
ferences in PRO-seq signal across splice junctions. These data strongly support the
assumption that Pol II travels at a uniform rate across splice junctions. Using the
median distance from splicing events to Pol II position in my combined data (142
nt) and taking into account the 0.5-6 kb/min range of measured Pol II elongation
rates (Jonkers and Lis, 2015), I calculate that the splicing events detected in my
data occurred within 1.4-17 seconds of intron transcription. These rates are simi-
lar to those obtained in budding and fission yeasts (Alexander et al., 2010a; Alpert
et al., 2020; Carrillo Oesterreich et al., 2016; Eser et al., 2016; Herzel et al., 2018).
4.4 Mechanism of Splicing Catalysis Delay
Due to the 3′ end chemistry and structure of splicing intermediates, I can capture
the step I intermediates of splicing with long-read sequencing. Remarkably, splic-
ing intermediates were distributed unevenly among introns and were associated
with poor sequence consensus at the downstream 3′SS. This evidence is consistent
with a model where modulation of the transition between catalytic steps of splicing
can alter splicing fidelity or outcome (Smith et al., 2008). Because the spliceosomes
associated with these intermediates have already assembled and undergone step I
chemistry, the accumulation of intermediates cannot be attributed to defective in-
tron recognition during spliceosome assembly. Instead, the catalytic center of the
spliceosome shifts from the branch site (step I) to the 3′SS AG (step II), typically
30-60 nt downstream of the branch site. The mechanism underlying 3′SS choice
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during this transition is likely to be influenced by spliceosomal proteins outside of
the catalytic core. A recent cryo-EM study of human spliceosomes has identified
several spliceosomal components that may be in a position to regulate the transi-
tion from step I to step II (Fica et al., 2019). Future studies of these enigmatic new
players may reveal a role for 3′SS diversity in the regulation of splicing by stalling
between catalytic steps.
4.5 Resolution of β-globin Splicing Measurements
My LRS data resolve a mystery shrouding β-globin pre-mRNA splicing. Two pre-
vious studies used stably integrated β-globin reporter genes combined with high
resolution fluorescence microscopy to track pre-mRNA transcription and splicing
in HEK293 and U2OS cells (Coulon et al., 2014; Martin et al., 2013). One study
reported data consistent with co-transcriptional splicing, while the other strongly
favored post-transcriptional splicing. The LRS data presented here explains that,
at least in MEL cells, there are two major populations of globin transcripts: “all
spliced” RNAs and “all unspliced” RNAs (Figure 3.19 A, Figure 3.20 A, Figure 3.21
B). Although previous studies also linked the splicing of β-globin exon 2 with 3′ end
cleavage (Antoniou et al., 1998; Dye and Proudfoot, 1999), here I show all-or-none
behavior in the splicing and cleavage decisions made by both α- and β-globins.
In any biochemical and/or short-read RNA-seq assay that examines populations
of pre-mRNA, inefficient splicing would be one explanation for the bulk result.
In reality, one population is unspliced and uncleaved at their 3′ ends. The other
population of globin transcripts is efficiently spliced and productively expressed,
because polyA cleavage and subsequent Pol II termination also occur efficiently for
these RNAs.
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4.6 Model for Mechanistic Link Between Splicing and
3′ End Cleavage
The fraction of efficiently spliced β-globin transcripts increased in the thalassemia
allele I studied, even though the cryptic 3′SS yields an out of frame mRNA that
will—like many thalassemia alleles of β-globin—be degraded by nonsense-mediated
decay (Kurosaki et al., 2019). Accordingly, a decrease in uncleaved reads extend-
ing beyond the PAS in the MEL-HBBIVS-110(G>A) cells was evident compared to the
MEL-HBBWT cells. This indicates that splicing efficiency is a determinant of 3′ end
cleavage. Several possible mechanisms could be involved. Less efficient splicing
can inhibit 3′ end cleavage (Cooke et al., 1999; Davidson and West, 2013; Martins
et al., 2011), suggesting that introns retained in transcripts that display readthrough
harbor an inhibitory activity that represses 3′ end cleavage (Figure 4.1). Candidate
inhibitory factors include U1 snRNP, PTB and hnRNP C proteins, each of which
binds introns promiscuously in vivo (Deng et al., 2020; König et al., 2010). In partic-
ular, U1 snRNP binding to introns is known to repress premature 3′ end cleavage
and cleavage at PASs (Berg et al., 2012; So et al., 2019; Vagner et al., 2000). I specu-
late that this inhibitory activity persists longer on inefficiently spliced transcripts,
potentially binding and inactivating 3′ end cleavage factors (Deng et al., 2020; So
et al., 2019). Additionally, the deposition of stimulatory factors—namely the exon
junction complex (EJC) and SR proteins—on exon-exon junctions after splicing may
stimulate splicing of the next intron (Singh et al., 2012), potentially contributing to
the all-spliced phenomenon. An added stimulus to 3′ end cleavage may also be af-
forded by loss of U1 snRNP and accumulation of SR proteins, since the RS domain
in Fip1 promotes cleavage (Zhu et al., 2018); more generally, SR proteins are asso-
ciated with polyA site choice (Müller-McNicoll et al., 2016). Thus, more efficient
splicing in the thalassemia mutant likely enables 3′ end cleavage by more quickly
105
removing inhibitory activities and/or recruiting positive effectors. Investigation of
these mechanisms awaits future studies that would afford single transcript eval-
uation of the residence time of intron-bound inhibitory factors (e.g. U1 snRNP)
coupled with splicing and cleavage outcome.
It is tempting to speculate that improving splicing efficiency could be a general
strategy for increasing gene output in a variety of disease settings. My findings
substantiate an earlier proposal based on experiments on β-globin that efficient
splicing and 3′ end cleavage contribute to gene expression output (Lu and Cullen,
2003), by suggesting that nascent transcripts are earmarked as productive or unpro-
ductive during their biogenesis. Moreover, failure of 3′ end cleavage when splicing
is impaired would explain why splicing efficiency was previously associated with
release of RNA from the site of transcription (Antoniou et al., 1998; Custodio et al.,
1999; Dye and Proudfoot, 1999). Importantly, many physiological stresses—such
as osmotic stress, heat shock, cancer, aging, and viral infection—cause a failure to
cleave at annotated PASs and the production of very long non-coding RNAs (Enge
et al., 2017; Grosso et al., 2015; Muniz et al., 2017; Vilborg et al., 2015, 2017). This
strong connection between splicing efficiency, 3′ end formation, and transcription
termination introduces previously unknown layers of regulation to mammalian





Several limitations to this study remain to be investigated further. First, the length
of long-reads are dependent on reverse transcriptase processivity when copying
RNA into cDNA. While I have taken steps to enrich for full-length transcripts in my
library generation, some RNAs are likely not fully reverse transcribed and captured
in this dataset. Advancements in strand-switching RT enzyme chemistry may im-
prove this in the future (Guo et al., 2020). The length of reads in this study also pre-
cludes analysis of complex alternative splicing events, such as cassette exon usage,
simply because it is difficult to capture longer reads. Second, I have not addressed
directly what the ultimate fate of unspliced and uncleaved nascent RNA is in these
cells. While in other studies, the Neugebauer lab found these transcripts were de-
graded by the nuclear exosome (Herzel et al., 2018), it remains to be tested directly.
Finally, a more rigorous test of my proposed mechanism linking splicing and 3′ end
cleavage would require tools to probe inhibition of both processes. While chemi-
cal inhibitors can be used to block spliceosome assembly globally, these drugs also
induce a general stress response in cells (Castillo-Guzman et al., 2020), including
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changes in transcription and 3′ end cleavage. Thus, future studies probing this
mechanism await specific reagents to test directly the link between splicing and
cleavage.
5.2 Future Directions
The experiments described in this thesis provide a detailed view of the coordination
between transcription and splicing that occurs during mammalian erythropoiesis.
They also raise new hypotheses to be tested. While MEL cells are a useful model
system, the field of erythropoiesis is increasingly moving toward using more bio-
logically relevant cell types. It would be interesting to observe nascent RNA pro-
cessing in mammalian hematopoietic stem and progenitor cells (HSPCs) induced
to undergo erythroid differentiation. As discussed in Chapter 1, it is known that
human and mouse erythroid cells undergo distinct transcriptomic changes dur-
ing terminal differentiation (An et al., 2014). I note a distinct lack of intron re-
tention in my LRS libraries after induction of erythropoiesis, and this may be in
part because intron retention is less pronounced in mouse. Indeed, the charac-
terized examples of intron retention during erythropoiesis have been observed in
human cells (Pimentel et al., 2016). Therefore, it would be extremely informative
to study co-transcriptional splicing in a human HSPCs. Additionally, we know
that erythroid cells undergo specific stresses, such as oxidative stress (Lee et al.,
2020). Due to the documented link between stress and readthrough transcription
(Castillo-Guzman et al., 2020), HPSCs would provide an ideal system for induc-
ing a biologically relevant stress and monitoring the effects on nascent RNA 3′ end
formation and splicing.
The intriguing connection between splicing and 3′ end formation discussed in
this thesis was uncovered using a β-globin mini gene which contained a thalassemia-
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causing point mutation. In fact, even in the endogenous context, the β-globin
gene is one of the most striking examples of genes harboring all unspliced tran-
scripts which fails to undergo 3′ end cleavage. Therefore, the β-globin minigene-
containing MEL cell lines provide ample opportunity for further exploration of
the mechanistic relationship between splicing and cleavage. For example, many
naturally-occurring mutations in the β-globin splice sites could be inserted into
the minigene, and the effect on 3′-end formation could be monitored by long-read
sequencing. Additionally, this could provide a useful model system for identify-
ing trans-acting factors which may link the two processes. For example, I speculate
that U1 snRNP could play a role in binding and suppressing the usage of spuri-
ous splice sites (Berg et al., 2012), but also in suppressing polyA cleavage if it is
not efficently removed from the pre-mRNA via splicing. It could be suggested then
that modulating levels of U1 snRNP (for example with U1 antisense morpholinos
(Kaida et al., 2010)) could affect the efficiency of 3′ end formation. To this end, the
level of other splicing accessory proteins, such as SR and hnRNP proteins, could
also be modulated to test their involvement in the process. Together, the molecu-
lar biology reagents and methods developed in this thesis present opportunities to
further dissect the mechanistic link between transcription elongation, splicing, and
3′ end formation in an erythroid system.
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Appendix
Table 5.1: Barcode sequences for custom RT primer.
Barcode Name Sequence Purification
RT BC 01 CACATATCAGAGTGCG PAGE
RT BC 02 ACACACAGACTGTGAG PAGE
RT BC 03 ACACATCTCGTGAGAG PAGE
RT BC 04 CACGCACACACGCGCG PAGE
RT BC 05 CACTCGACTCTCGCGT PAGE
RT BC 06 CATATATATCAGCTGT PAGE
RT BC 07 TCTGTATCTCTATGTG PAGE
RT BC 08 ACAGTCGAGCGCTGCG PAGE
RT BC 09 ACACACGCGAGACAGA PAGE
RT BC 10 ACGCGCTATCTCAGAG PAGE
RT BC 11 CTATACGTATATCTAT PAGE
RT BC 12 ACACTAGATCGCGTGT PAGE
RT BC 13 CTCTCGCATACGCGAG PAGE
RT BC 14 CTCACTACGCGCGCGT PAGE
RT BC 15 CGCATGACACGTGTGT PAGE
RT BC 16 CATAGAGAGATAGTAT PAGE
RT BC 17 CACACGCGCGCTATAT PAGE
RT BC 18 TCACGTGCTCACTGTG PAGE
RT BC 19 ACACACTCTATCAGAT PAGE
RT BC 20 CACGACACGACGATGT PAGE
RT BC 21 CTATACATAGTGATGT PAGE
RT BC 22 CACTCACGTGTGATAT PAGE
RT BC 23 CAGAGAGATATCTCTG PAGE
RT BC 24 CATGTAGAGCAGAGAG PAGE
Sequences that can be used as a barcode during the reverse transcription step
of long-read sequencing library preparation.
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Table 5.2: RNA sequencing read counts
Sample Protocol Raw Mapped Non PolyA Non 7SK Unique Non Intermediates
Uninduced LRS 1,036,691 583,632 576,607 453,009 429,099 402,316
Induced LRS 720,882 571,997 559,718 395,793 255,182 233,942
HBBWT targeted LRS 68,784 70,871 37,642 NA 37,275 33,571
HBBIVS-110(G>A) targeted LRS 79,833 78,948 32,172 NA 31,885 28,323
Uninduced PRO-seq 220,070,650 127,803,736 N/A N/A N/A N/A
Induced PRO-seq 208,414,166 109,366,055 N/A N/A N/A N/A
Read counts representing raw reads, mapped reads, polyA-filtered reads, 7SK-
filtered reads, unique reads, and non-splicing intermediate reads (where applica-
ble) for genome-wide LRS, HBB-targeted LRS, and PRO-seq. LRS samples repre-
sent combined counts for two biological and two technical replicates in each induc-
tion condition, and PRO-seq samples represent combined counts for three biologi-
cal replicates in each induction condition.
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Table 5.3: Oligonucleotide sequences used in this thesis.
Description Sequence
3′ end DNA adapter /5rApp/NNNNNCTGTAGGCACCATCAAT/3ddC/
genome-wide RT AAGCAGTGGTATCAACGCAGAGTACATTGATGGTGCCTACAG
targeted RT barcode 1 AAGCAGTGGTATCAACGCAGAGTACCACATATCAGAGTGCGGATTGATGGTGCCTACAG
targeted RT barcode 2 AAGCAGTGGTATCAACGCAGAGTACACACACAGACTGTGAGGATTGATGGTGCCTACAG
targeted RT barcode 3 AAGCAGTGGTATCAACGCAGAGTACACACATCTCGTGAGAGGATTGATGGTGCCTACAG
targeted RT barcode 4 AAGCAGTGGTATCAACGCAGAGTACCACGCACACACGCGCGGATTGATGGTGCCTACAG
targeted RT barcode 5 AAGCAGTGGTATCAACGCAGAGTACCATATATATCAGCTGTGATTGATGGTGCCTACAG
targeted RT barcode 6 AAGCAGTGGTATCAACGCAGAGTACTCTGTATCTCTATGTGGATTGATGGTGCCTACAG
targeted PCR human HBB GACGTGTGCTCTTCCGATCTCACGACACGACGATGTcaactgtgttcactagcaacct
qPCR F Hbb-b1 ATGCCAAAGTGAAGGCCCAT
qPCR R Hbb-b1 CCCAGGAGCCTGAAGTTCTC
qPCR F Gapdh AATGTGTCCGTCGTGGATCTGA
qPCR R Gapdh GATGCCTGCTTCACCACCTTCT
RT-PCR F Brd2 GATTATCACAAAATTATAAAACAGCC
RT-PCR R Brd2 CTGCTAACTTGGCCCCC
RT-PCR F Dnajb1 CCTTTCCCAAGGAAGGG
RT-PCR R Dnajb1 GTTTCTCAGGTGTTTTGGG
RT-PCR F Riok3 TGTTGCTGAAGGACCATTC
RT-PCR R Riok3 ATTTTCCATTCTTGCTGTGTTC
RT-PCR F Slc12a6 GACGTGTGCTCTTCCGATCTGGATAACATCATACCTTTCCTTAGG
RT-PCR R Slc12a6 ATGGAAAGAATTGGGGCC
RT-PCR F Dmtn GACGTGTGCTCTTCCGATCTCCACCCATCTACAAACAGAGAG
RT-PCR Dmtn CCACAACGGCCAGCGACG
RT-PCR F Hnrnpll GACGTGTGCTCTTCCGATCTTAAAGTGTTTGACGCGAAAG
RT-PCR R Hnrnpll TCGGGACTCGTATCTGGTA
RT-PCR F Rbm39 GACGTGTGCTCTTCCGATCTTGCCTCATAGCATCAAATTAAG
RT-PCR R Rbm39 CTCACAGGGCTCTTGTCTT
RT-PCR F Hbq1b GACGTGTGCTCTTCCGATCTGGACCCTGCTAACTTCCAG
RT-PCR R Hbq1b TCAGCGATATTTGGAGACC
RT-PCR F C1qbp GACGTGTGCTCTTCCGATCTCACAGATTCCCTGGACTGG
RT-PCR R C1qbp CTACTGGTTCTTGACAAAGCTTT
VRA3 3′ end adapter /5Phos/rGrArUrCrGrUrCrGrGrArCrUrGrUrArGrArArCrUrCrUrGrArArC/3InvdT/
VRA5 5′ end adapter rCrCrUrUrGrGrCrArCrCrCrGrArGrArArUrUrCrCrA
RP1 primer AATGATACGGCGACCACCGAGATCTACACGTTCAGAGTTCTACAGTCCGA
/5rApp/ = activated adenylate; /3ddC/ = dideoxycytosine; /5Phos/ = phosphorylated; /3InvdT/ = inverted base; rN
= ribonucleotide base
Oligonucleotide sequences used in this study for LRS library preparation, qPCR,
RT-PCR, and PRO-seq library preparation.
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Table 5.4: Key Resources
REAGENT or RESOURCE SOURCE IDENTIFIER
Antibodies
Rabbit polyclonal anti-GAPDH Santa Cruz Biotechnology FL-335/sc-25778
Mouse monoclonal anti-Pol II Santa Cruz Biotechnology CTD4H8/sc-47701
Chemicals, Peptides, and Recombinant Proteins
DMEM + GlutaMAX Gibco 10569-010
Fetal Bovine Serum (FBS) Gibco 16000-044
Penicillin Streptomycin Gibco 15140-122
α-Amanitin Sigma A2263
SUPERase.In ThermoFisher AM2694
1X cOmplete Protease Inhibitor Cocktail Sigma 11697498001
TRIzol Reagent ThermoFisher 15596018
RNase-Free DNase Set Qiagen 79254
Pladienolide B Santa Cruz Biotechnology 445493-23-2
Random Hexamer Primers ThermoFisher SO142
Phusion High-Fidelity DNA Polymerase NEB M0530S
Biotin-11-NTPs Perkin-Elmer NEL54(2/3/4/5)001
Critical Commercial Assays
RNeasy Mini Kit Qiagen 74104
Dynabeads mRNA DIRECT Micro Purification Kit ThermoFisher 61021
Ribo-Zero Gold rRNA Removal Kit Illumina MRZG126
T4 RNA ligase Kit NEB M0351L
SMARTer PCR cDNA Synthesis Kit Clontech 634925
Advantage 2 PCR Kit Clontech 639201
AMPure XP Beads Agencourt A63880
SuperScriptIII Reverse Transcriptase ThermoFisher 18080044
iQ SYBR Green Supermix Biorad 1708880
SMRTbell Template Prep Kit 1.0 Pacific Biosciences 100-259-100
Total RNA Purification Kit Norgen Biotek Corp. 17200
Dynabeads M-280 Streptavidin ThermoFisher 11205D
T4 RNA Ligase I NEB M0204S
ThermoPol Reaction Buffer NEB B9004S
RNA 5′ Pyrophosphohydrolase (RppH) NEB M0356S
T4 Polynucleotide Kinase NEB M0201S
Lysis Buffer, FS ThermoFisher 4480724
SuperScript IV Reverse Transcriptase ThermoFisher 18090010
ProNex Size-Selective Purification System Promega NG2001
Deposited Data
continued on next page...
113
REAGENT or RESOURCE SOURCE IDENTIFIER
Raw and analyzed data This thesis GEO: GSE144205
Raw image data This thesis http://dx.doi.org/10.
17632/5vrtbpnj4k.1
nanoCOP data from BL1184, K562, and S2 cells (Drexler et al., 2020) GEO: GSE123191
total RNA-seq from MEL cells Mouse ENCODE (Stamatoy-
annopoulos et al., 2012)
ENCSR000CWE
Code for LRS data analysis This thesis https://github.com/
NeugebauerLab/MEL_LRS
Experimental Models: Cell Lines
MEL Shilpa Hattangadi N/A
MEL-HBBWT (Patsali et al., 2018) N/A
MEL-HBBIVS-110(G>A (Patsali et al., 2018) N/A
Oligonucleotides
See Table 5.3 This thesis N/A
Software and Algorithms
Porechop v0.2.4 N/A https://github.com/
rrwick/Porechop
Cutadapt v1.9.1 (Martin, 2011) https://cutadapt.
readthedocs.io/en/stable/
Bowtie v1.2.2 (Langmead et al., 2009) http://bowtie-bio.
sourceforge.net/index.
shtml
STAR v2.7.0a (Dobin et al., 2013) http://code.google.com/p/
rna-star/
Prinseq-lite v0.20.4 (Schmieder and Edwards, 2011) https://sourceforge.net/
projects/prinseq/files/
Minimap2 v2.12-r827 (Li, 2018) https://github.com/lh3/
minimap2
samtools v1.9 (Li et al., 2009) http://samtools.
sourceforge.net/
bedtools v2.27.1 (Quinlan and Hall, 2010) https://bedtools.
readthedocs.io/en/latest/




deepTools v3.3.0 (Ramirez et al., 2016) https://deeptools.
readthedocs.io/en/
develop/
continued on next page...
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